Interleukin 21 controls tumor growth  and tumor immunosurveillance in colitis-associated tumorigenesis in mice by Jauch, Dominik
 
 
 
 
 
 
 
AUS DEM LEHRSTUHL FÜR CHIRURGIE 
PROF. DR. H. J. SCHLITT 
 
DER FAKULTÄT FÜR MEDIZIN 
DER UNIVERSITÄT REGENSBURG 
 
 
 
 
 
 
Interleukin 21 controls tumor growth and tumor 
immunosurveillance in colitis-associated tumorigenesis 
in mice 
 
 
 
 
Inaugural – Dissertation 
zur Erlangung des Doktorgrades 
der Medizin 
 
 
 
der 
Fakultät für Medizin 
der Universität Regensburg 
 
 
 
 
vorgelegt von  
DOMINIK JAUCH 
 
 
 
 
2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUS DEM LEHRSTUHL FÜR CHIRURGIE 
PROF. DR. H. J. SCHLITT 
 
DER FAKULTÄT FÜR MEDIZIN 
DER UNIVERSITÄT REGENSBURG 
 
 
 
 
 
 
Interleukin 21 controls tumor growth and tumor 
immunosurveillance in colitis-associated tumorigenesis 
in mice 
 
 
 
 
Inaugural – Dissertation 
zur Erlangung des Doktorgrades 
der Medizin 
 
 
 
der 
Fakultät für Medizin 
der Universität Regensburg 
 
 
 
 
vorgelegt von  
DOMINIK JAUCH 
 
 
 
 
2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dekan:    Prof. Dr. Dr. Torsten E. Reichert 
 
1. Berichterstatter:   Prof. Dr. Stefan Fichtner-Feigl 
 
2. Berichterstatter:   Prof. Dr. Dr. Andreas Teufel 
 
Tag der mündlichen Prüfung: 10. März 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Für meine Familie und Freunde 
 
 
 
 
 
 
 
 
 
Inhaltsverzeichnis 
 
                   
Seite 
 
Abbildungsverzeichnis        III 
 
Abkürzungsverzeichnis        IV 
 
 
1 Zusammenfassung der Publikation 
 1.1 Einleitung         5 
 1.2 Methoden         7 
 1.3 Ergebnisse         8 
 1.3.1 Chronische Kolitis       8 
 1.3.2 Kolitis-induzierte Tumorentstehung    10 
 1.3.2.1 Funktion von IFN-γ bei der Kolitis-induzierten  11
    Tumorentstehung       
 1.3.2.2 CD8+ T-Zell vermittelte Tumor-Immunosurveillance 12 
 1.4 Diskussion         15 
 
 
2 Interleukin 21 controls tumor growth and tumor   
immunosurveillance in colitis-associated tumorigensis 
in mice 
D.Jauch et al., Gut, 2011. 
 2.1 Published article        18 
 2.2 Supplementary Figures       27 
 2.3 Commentary         36 
 S.Danese, A.Malesci, S.Vetrano, Gut, 2011. 
 2.4 Authors view        38 
 R.Kesselring, D.Jauch, S.Fichtner-Feigl, OncoImmunology, 2012.  
I
 
 
 
3 Adenoma - linked barrier defects and microbial  
products drive IL-23/IL-17 - mediated tumor growth 
S.Grivennikov & K.Wang, D. Jauch et al., Nature, 2012. 
 3.1 Published article        40 
 3.2 Supplementary Information      47 
 
Literaturverzeichnis         59 
 
Lebenslauf          61 
 
Eidesstattliche Erklärung        64 
 
Danksagung          65 
 
II
 
 
 
Abbildungsverzeichnis 
       Seite 
 
Abb. 1:  Immunosurveillance, Tumor-promoting inflammation   6 
 
Abb. 2:  Histology score bei einer chronischen DSS-Kolitis    9 
 
Abb. 3:  Zytokinexpression von CD4+ T-Zellen aus MLN bei    9 
    chronischer DSS-Kolitis 
 
Abb. 4:  Tumoranzahl an Tag 42 bei Kolitis-induzierter Tumorgenese  10 
 
Abb. 5:  Tumoranzahl an Tag 70 bei Kolitis-induzierter Tumorgenese  10 
 
Abb. 6:  Zytokinexpression an Tag 42 von CD4+ LPMC mittels ELISA   11 
    bei Kolitis-induzierter Tumorentstehung 
 
Abb. 7:  Tumoranzahl nach IFN-γ Blockierung an Tag 42    12 
 
Abb. 8:  CD103/CD8, Granzyme B und Perforin Expression,    13 
    FACS von LPMC an Tag 28 
 
Abb. 9:  Zytotoxizität von CD8+ LPMC an Tag 28     14 
 
Abb. 10: TUNEL-Assay von Tumoren an Tag 42     14 
 
Abb. 11: Schematische Charakteristik des Tumorwachstums in    16 
   Abwesenheit 16 von IL-21 im Vergleich zu einem  
   IL-21 reichen Tumormilieu     
 
 
III
 
 
 
Abkürzungsverzeichnis 
 
APC   adenomatous polyposis coli 
β-catenin  catherin-associated protein beta  
k-ras   Kirsten rat sarcoma viral oncogene homolog 
IβL   Interleukin 
Th   T-Helfer-Zelle 
TNF-α  Tumor-Nekrosefaktor-alpha 
IFN-γ   Interferon-gamma 
CD   Cluster of differentiation 
NK-Zellen  Natürliche Killer-Zellen 
IL-21-/-  homozygote Interleukin-21 Defizienz 
AOM   Azoxymethan 
i.p.   intraperitoneal 
DSS   dextran sodium sulfate 
MLN   Mesenteriale Lymphknoten 
LPMC   lamina propria mononuclear cells 
H&E   Hämatoxylin-Eosin Färbung 
Alcian blue-PAS Periodic acid-Schiff reaction Färbung 
Ki-67   Kiel 67 
E-Cadherin  epitheliales Cadherin 
TUNEL-Assay TdT-mediated dUTP-X nick end labeling 
DNA   Desoxyribonukleinsäure 
MACS  magnetic bead sorting 
ELISA   enzyme-linked immunosorbent assay 
FACS   fluorescence-activated cell sorting 
CTL-Assay  cytotoxic T-lymphocyte assay 
CT-26 Zellen  murine Kolonkarzinomzelllinie 
NKT Zellen  Natürliche Killer T-Zellen 
GM1   Gangliosid Monosialogangliosid 1 
IV
 
1  Zusammenfassung 
 
 
1.1 Einleitung 
 
Darmkrebs stellte in Deutschland mit 62.430 Neuerkrankungen im Jahr 2010 die 
zweithäufigste Tumorerkrankung dar [1]. Grundsätzlich kann man drei verschiedene 
Entstehungsmechanismen unterscheiden. Die Mehrzahl der Malignome, mit bis zu 
95% treten sporadisch auf. Die weiteren Fälle entstehen hereditär oder aufgrund von 
chronisch entzündlichen Darmerkrankungen, wie zum Beispiel der Kolitis ulzerosa.  
Patienten mit einer Kolitis ulzerosa haben ein deutlich erhöhtes Risiko im Laufe ihres 
Lebens ein Kolorektales Karzinom zu entwickeln. Das kumulative Risiko ein 
Karzinom nach 10 Erkrankungsjahren zu entwickeln beträgt 2% und steigt nach 20 
Jahren auf 8% und nach 30 Jahren auf 18% an [2]. Ob das Risiko aufgrund besserer 
Therapien, frühzeitiger Diagnosestellung und kurativer Operationsmethoden 
reduziert wird kann derzeit noch nicht sicher beurteilt werden [3]. 
 
Zur Etablierung einer Präventionsstrategie ist somit die Aufklärung des 
Pathomechanismus chronisch entzündlicher Darmerkrankungen unumgänglich. 
Während die sporadischen und die hereditären Neuerkrankungen 
molekulargentisch weitgehend beschrieben sind, bleiben die genauen 
immunologischen Mechanismen der entzündungsassoziierten Darmkrebsentstehung 
noch ungeklärt.  
Die sporadische Darmkrebsentstehung folgt oftmals einer Sequenz genetischer 
Veränderungen, basierend auf dem Verlust des Tumorsuppressorgens APC und 
folgender β-Catenin Aktivierung und k-ras Mutation. Zugrunde liegt hierbei die 
Adenom-Karzinom-Sequenz mit einer Zunahme von molekulargenetischen 
Veränderungen und Zellproliferation. Auch ohne existente Entzündung werden in 
diesen Tumoren entzündliche Infiltrate gefunden. Die Aktivierung des 
Immunsystem erfolgt hierbei jedoch im Unterschied zur Kolitis-assoziierten 
Tumorentstehung intrinsisch durch, vom Tumor exprimierte Antigene [4]. 
 
Beiden, der sporadischen und der entzündungsvermittelten Tumorentstehung, ist 
ein spezielles immunologisches Tumormilieu gemein. Charakterisiert ist dies 
einerseits durch zytotoxische, tumorbekämpfende T-Zellen, anderseits gleichzeitig 
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durch Tumorproliferation begünstigende T-Helfer-Zellen. Proinflammatorische 
Zytokine werden von tumorinfiltrierenden T-Helfer-Zellen produziert. Hierzu 
zählen vor allem IL-1, IL-6, IL-17, IL-23, IFN-γ und TNF-α. Interleukin-21 ist dabei 
von besonderer Bedeutung, da dieses Zytokin maßgeblich an der Polarisierung von 
zwei Subtypen der T-Helfer-Zellen beteiligt ist, der Th-1 und Th-17 Zelle. Die 
Sekretion dieses Zytokins erfolgt durch NK-Zellen und Th-17 Zellen.  
 
Ferner spielt auch die Tumor-Immunosurveillance - eine immunologisch gesteuerte 
Tumorbekämpfung - eine tragende Rolle in der Regulation des Wachstums 
entzündsassoziierter Malignome. Vermittelt wird dies durch zytotoxische CD8 T-
Zellen und NK-Zellen. Die Produktion von Perforinen und Granzyme sorgen hierbei 
für Apoptose der Tumorzellen und regulieren das Tumorwachstum. 
 
 
 
Ziel dieser Arbeit ist es, herauszufinden inwieweit Interleukin-21 Einfluss auf die 
entzündungsassoziierte Tumorentstehung im Kolon nimmt und im Rahmen dieser 
das Zytokinmilieu beeinflusst. 
Abb. 1: Immunosurveillance, Tumor-promoting inflammation, modifiziert nach [5].  
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1.2 Methoden 
 
IL-21-/- (B6;129S5) und wild-typ Kontrolltiere wurden pathogen frei gehalten. Für die 
Tierversuche wurden alle Tiere genetisch bezüglich der IL-21-Defizienz analysiert 
und im Alter von 2-4 Wochen für die Versuche ausgewählt. Für die Tierversuche 
wurden je Gruppe 10 Tiere untersucht. 
 
Die chronische Kolitis wurde unter Verabreichung von abwechselnd 7 Tagen 1,5% 
DSS Trinklösung und 7 Tagen Trinkwasser für insgesamt 3 Zyklen induziert. Zur 
Einleitung der Tumorentstehung wurden 10mg/kg Körpergewicht AOM initial an 
Tag 1 i.p. injektziert. Gewichtskontrollen wurden wöchentlich durchgeführt. Die 
Auswertung erfolgte am Endpunkt nach 42 bzw. 70 Tagen. 
Analysiert wurden die Versuchstiere hinsichtlich: 
• Tumoranzahl und -größe 
• Histologie und Immunhistochemie der Tumore und entzündeter Areale 
• Zytokinproduktion von MLN und LPMC  
• T-Zell Zytotoxizität 
 
Die Tumoranzahl wurde makroskopisch nach Beenden der Versuchstiere bestimmt 
und deren Größe anschließend histologisch, mithilfe der Mirax Viewer Software, 
Carl Zeiss AG, verifiziert. 
 
Für die histologische Beurteilung wurden Teilstücke des Kolons, tumortragende und 
entzündlich veränderte, in Formalin fixiert und anschließend durch das Institut für 
Pathologie der Universität Regensburg in Paraffin gebettet. Die 
Entzündungsreaktion wurde anhand eines histology scores [6] von H&E gefärbten 
Gewebeschnitten verblindet quantifiziert. 
Immunhistochemische Gewebefärbungen erfolgten nach Anleitung der 
Antikörperhersteller. Alcian blue-PAS Färbungen zeigen die Verteilung von Schleim-
produzierenden Becherzellen im Epithel an, Ki-67 gibt Aufschluss über die 
Proliferation der Epithelzellen, β-Catenin und E-Cadherin positive Signale 
beschreiben die Degradation der Zellwand-Barrierefunktion, Foxp3 färbt 
regulatorische T-Zellen an, anti-INF-γ und anti-CD-8 Antikörper reagieren jeweils 
mit Zytokin produzierenden bzw. Zelloberflächenstrukturen exprimierenden Zellen. 
Der TUNEL-Assay färbt frühapoptische Zellen bzw. deren DNA-Strangbrüche 
mithilfe von Fluoreszin-gebundenem Uracil an. 
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CD4 und CD11b positive Zellen wurden mit Hilfe der MACS-Technik aus MLN oder 
LPMC isoliert und für 48 Stunden mit anti-CD3 und anti-CD28 Antikörpern 
kultiviert. Die Bestimmung der Zytokinkonzentration erfolgte mittels ELISA 
Messung des kultivierten Überstands. 
 
Zur Bestimmung der CD103-, Granzyme B- und Perforin-Expression wurden LPMC 
isoliert und mit entsprechenden fluoreszenz-markierten Antikörpern markiert. Die 
darauffolgende FACS-Analyse der markierten Zellen gibt dann Aufschluss über die 
jeweils prozentual positiv gefärbten Zellen der gesamten Zellpopulation. 
 
Erkenntnis über die zytotoxische Aktivität CD8+ Zellen lieferte der CTL assay. 
Hierbei wurden CD8+ LPMC isoliert und mit CT-26 Zellen, E-Cadherin-transfiziert 
oder nativ, kokultiviert. Die zytotoxische Aktivität wurde nach 24 Stunden mit einem 
Luminescent Cell Viability Assay bestimmt. 
 
Die statische Auswertung erfolgte mit Hilfe der Software GraphPad Prism, Werte 
von p<0.05 wurden als signifikant bezeichnet. 
 
 
1.3 Ergebnisse 
 
1.3.1 Chronische Kolitis 
 
Vorversuche konnten zeigen, dass IL-21 in chronischen und akuten Kolitiden in 
Mäusen, auch ohne Tumorwachstum deutlich hochreguliert ist. Gleichermaßen 
zeigen sich erhöhte IL-21 Level in Patienten mit ulzerativer Kolitis oder Morbus 
Crohn [7]. Zudem scheint es einen genetischen Zusammenhang zwischen 
Veränderungen im IL-2/IL-21 Lokus und der Entwicklung von chronisch-
entzündlichen Darmerkrankungen zu geben [8].  
 
In Abwesenheit von IL-21 konnte in einer chronischen DSS-Kolitis kaum eine 
Entzündungsreaktion nachgewiesen werden.  
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Wohingegen wild-typ Mäuse eine schwere Kolitis, mit Verlust der epithelialen 
Struktur entwickelten und ein deutlich erhöhtes proinflammatorischer Zytokinlevel 
(IL-17A , IFN-γ) aufwiesen. Ähnliche Resultate konnten im Rahmen der Transfer-
Kolitis gezeigt werden. Zudem zeigten IL-21-/- Mäuse eine signifikant reduzierte 
Proliferation von Epithelzellen, intraepithelialen und submukösen Lymphozyten.  
 
 
 
 
 
 
 
 
Abb. 2: Histology score bei einer chronischen DSS-Kolitis. 
Abb. 3: Zytokinexpression von CD4+ T-Zellen aus MLN bei chronischer DSS-Kolitis. 
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1.3.2 Kolitis-induzierte Tumorentstehung 
 
Im Tiermodell der Kolitis-assoziierten Tumorentstehung konnten wir in IL-21-/- 
durchschnittlich nur 1 Tumor pro Maus evaluieren, wohingegen wild-typ Mäuse im 
Durchschnitt 8 Tumoren aufwiesen. Die Tumore waren zudem in der 
Vergleichsgruppe größer und wiesen auch eine signifikant erhöhte Proliferationsrate 
innerhalb des Tumorgewebes auf. Auch im Langzeitversuch über 10 Wochen 
entwickelten IL-21 defiziente Mäuse nicht mehr Tumoren wie bereits nach 6 Wochen, 
bei den wild-typ Mäusen verdoppelte sich jedoch nahezu die Tumoranzahl. 
 
 
                      
 
 
Die Bestimmung des Zytokinmilieus in entzündeten und tumorösen Anteilen der 
Kolonschleimhaut zeigt, dass in beiden Arealen die IL-17A Produktion in IL-21--/- 
Mäusen signifikant reduziert ist. Hinsichtlich der IFN-γ Produktion ließ sich jedoch 
das Gegenteil nachweisen, in Abwesenheit von IL-21 ist die Produktion von IFN-γ 
gegenüber der wild-typ Mäuse deutlich gesteigert. Andere proinflammatorische und 
antiapoptotisch wirkende Zytokine wie IL-6 und IL-22 zeigten keine 
unterschiedlichen Expressionsmuster in beiden Versuchsgruppen.  
 
 
 
 
 
Abb. 4: Tumoranzahl an Tag 42 bei 
Kolitis-induzierter Tumorgenese. 
Abb. 5: Tumoranzahl an Tag 70 bei 
Kolitis-induzierter Tumorgenese. 
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1.3.2.1 Funktion von IFN-Υ bei der Kolitis-induzierten 
Tumorentstehung 
 
Der Schweregrad der chronischen Entzündungsreaktion zeigte trotz des 
unterschiedlichen Zytokinmilieus und der veränderten Tumorproliferation keine 
Unterschiede. Nur in der frühen Phase der Kolitis-induzierten Tumorentstehung 
ließen sich Unterschiede im Schweregrad der Entzündung im Kolonepithel 
feststellen. Begleitend dazu zeigte sich auch, dass IL-21-/- Mäuse erst im Verlauf der 
3. Woche eine überschießende IFN-γ zeigten.  
Inwieweit antigenpräsentierende Zellen und deren Zytokine Einfluss auf die 
Entzündungsreaktion und das Tumorwachstum nehmen wurde durch die 
Zytokinexpression CD11b positiver Zellen hinsichtlich IL-12 und IL-23 bestimmt. Es 
war dabei zu beobachten, dass IL-23 in wild-typ Mäusen deutlich hochreguliert ist, 
wohingegen IL-12p70 in IL-21-/- Mäusen eine höhere Expression aufwies. Somit sind 
auch antigenpräsentierende Zellen, zumindest teilweise an der Immunantwort der 
Kolitis-assoziierten Tumorentstehung beteiligt. 
 
Die Rolle von IFN-γ in der chronischen Kolitis mit Tumorwachstum wurde durch 
weitere Analysen und Experimente bestimmt. Hierfür wurde die chronische DSS-
Kolitis mit initialer AOM-Injektion durch die Gabe von anti-INF-γ Antikörpern ab 
Tag 14 ergänzt. Der Schweregrad der Kolitis in wild-typ Mäusen blieb davon 
unbeeinflusst in IL-21-/- Mäusen führte es jedoch zu einer signifikanten Reduktion 
Abb. 6: Zytokinexpression an Tag 42 von CD4+ LPMC mittels ELISA bei Kolitis-induzierter 
Tumorentstehung. 
. 
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der Kolitis. Hinsichtlich der Tumoranzahl beider Versuchsgruppen zeigten wild-typ 
Mäuse keine veränderte Tumoranzahl. In IL-21 defizienten Mäusen stieg die Anzahl 
der Tumore unter Blockierung von IFN-γ signifikant an.  
Somit kann man folgern, dass IFN-γ zumindest in IL-21-/- Mäusen, sowohl die 
Entzündungsreaktion, als auch die Entzündungs-vermittelte Tumorentstehung 
reguliert.  
 
 
 
 
 
 
 
1.3.2.2 CD8+ T-Zell vermittelte Tumor-Immunosurveillance 
 
CD8+ zytotoxische T-Zellen besitzen die Möglichkeit, auch unter Einfluss von IFN-γ 
das Tumorwachstum zu begrenzen. Unter Administration von anti-CD8 Antikörpern 
konnte in beiden Versuchsgruppen eine Reduktion der Tumorgröße und der 
Tumoranzahl erreicht werden. Die Kolitis blieb von der Antikörpertherapie 
unbeeinflusst. 
Auch können NK- und NKT-Zellen einen zytolytischen Effekt ausüben, dieser 
konnte in unseren Versuchen unter Gabe von CD1 und asialo-GM1 Antikörpern 
nicht nachgewiesen werden.  
CD8/CD103+ T- Zellen können Tumorwachstum regulieren, indem sie den Liganden 
E-Cadherin auf Tumorzellen binden. Das Expressionsmuster beider 
Versuchsgruppen hinsichtlich E-Cadherin in den Tumoren zeigte keine 
Abb. 7: Tumoranzahl nach IFN-γ Blockierung an Tag 42. 
12
Unterschiede, so dass ein zytolytischer Angriffspunkt in wild-typ und IL-21-/- 
Tumoren zur Verfügung steht. FACS - Analysen zeigten jedoch, dass wild-typ Mäuse 
im Tumormodell weniger CD8/CD103+ T-Zellen besitzen. Neben der quantitativen 
ist auch die qualitative zytotoxische Kapazität in wild-typ CD8/CD103+ T-Zellen 
vermindert. Granzyme B wird von IL-21-/- zytotoxischen T-Zellen, verglichen mit 
wild-typ Zellen, deutlich vermehrt ausgeschüttet. Hinsichtlich Perforin, einem 
weiteren apoptotisch wirksamen Zytokin konnte nur eine gering erhöhte Produktion 
von IL-21 defizienten T-Zellen gezeigt werden.  
 
 
 
 
 
 
Die zytotoxische Kapazität von isolierten CD8+ T-Zellen wurde des Weiteren 
gegenüber einer allogenen Kolontumorzelllinie getestet. Zusätzlich wurden diese 
CT-26 Zellen mit einem E-Cadherin (ein CD103 Ligand) exprimierendem Plasmid 
transfiziert. Wild-typ CD8+ T-Zellen entwickelten nur eine geringe zytolytische 
Aktivität gegenüber nativen CT-26 Zellen, jedoch eine erhöhte Aktivität gegen E-
Cadherin positive Kolontumorzellen. CD8+ T-Zellen aus IL-21 defizienten Mäusen 
zeigten eine höhere zytotoxische Aktivität sowohl gegenüber nativer als auch 
gegenüber E-Cadherin transfizierten Kolontumorzellen.  
Abb. 8: CD103/CD8, Granzyme B und Perforin Expression, 
FACS von LPMC an Tag 28. 
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Diese zytotoxisch vermittelte Apoptose konnte auch immunhistochemisch durch 
einen TUNEL-Assay verifiziert werden. In Tumoren von IL-21--/- Mäusen konnten 
deutlich mehr apoptotische Zellen nachgewiesen werden.  
 
 
         
 
 
Eine Inhibition von IFN-γ führte zu einem Rückgang CD8/CD103+ T-Zellen und 
verminderte somit die zytotoxische Kapazität dieser Zellpopulation. 
Daraus konnten wir feststellen, dass das Vorkommen zytotoxischer CD8/CD103+ T-
Zellen in IL-21 defizienten Mäusen abhängig von der IFN-γ Konzentration ist.  
 
Abb.10: TUNEL-Assay von Tumoren an Tag 42. 
Abb. 9: Zytotoxizität von CD8+ LPMC an Tag 28. 
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1.4 Diskussion 
 
Die Ätiologie chronisch entzündlicher Darmerkrankungen, wie Morbus Crohn und 
Kolitis ulzerosa, ist noch nicht hinreichend aufgeklärt. Eine der schwerwiegenden 
Langzeitkomplikation der Kolitis ulzerosa ist die Entstehung von kolorektalen 
Karzinomen.  
 
Immunologisch wird die chronische Entzündungsreaktion durch eine Vielzahl von 
proinflammatorischen Zytokinen, wie z.B. IL-21 charakterisiert. Wir konnten hier 
zeigen, dass IL-21 entscheidend an der Polarisierung proinflammatorischer T-Helfer 
Zellen beteiligt ist, im Besonderen der Th-17 Zelle.  
Neben der Tumorproliferation spielt auch die Tumor-Immunosurveillance eine 
tragende Rolle in der Entwicklung von Entzündungs-assoziierten Tumoren. IL-21 
trägt in unserem Tiermodell dazu bei, dass sich das Zytokinmilieu in Tumoren 
verändert und damit auch Einfluss auf die körpereigene Tumorregulation nimmt. 
 
In der experimentellen, chronischen Kolitis konnte nahezu keine 
Entzündungsreaktion in Abwesenheit von Interleukin-21 beobachtet werden. 
Niedrige IL-17 und IFN-γ Konzentrationen bewahrten die Versuchstiere vor der 
Entwicklung einer chronischen Kolitis.  
Im Kolitis-induzierten Tumorwachstum konnte bei beiden Versuchsgruppen eine 
Entzündungsreaktion beobachtet werden. Gekennzeichnet war diese in wild-typ 
Tieren erneut durch eine hohe Produktion von IL-17. Hingegen zeigten sich in IL-21 
defizienten Mäusen hohe IFN-γ Konzentrationen, welche die Kolitis hervorriefen.  
Die mukosale Entzündung beeinflusst das immunologische Tumormilieu nachhaltig 
und führt in kolorektalen Karzinomen zu einer Infiltration von Th-17 Zellen [9]. In 
dieser Arbeit war das Kolitis-assoziierte Tumorwachstum in wild-typ Mäusen durch 
eine hohe IL-17A Produktion und eine verringerte IFN-γ Konzentration 
gekennzeichnet. Ebenfalls zeigen unsere Ergebnisse, dass das Vorkommen dieser 
zwei T-Zell Subtypen entscheidend durch IL-21 bestimmt wird. 
In Abwesenheit von IL-21 war die Entzündungsreaktion durch hohe IFN-γ und 
niedrige IL-17A Konzentration gekennzeichnet. Die Reduktion der Tumorentstehung 
ist dabei in unserer Arbeit nicht auf eine ausbleibende Kolitis zurückzuführen, 
sondern vielmehr Resultat des veränderten Tumormilieus. Stolfi et al kamen dagegen 
zu dem Ergebnis, dass genau diese ausbleibende Entzündung zu einer Reduktion 
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der Tumoranzahl in IL-21-/- Mäusen geführt hat [10]. Diese Reduktion der 
Entzündung konnte in unseren Experimenten jedoch nur in der chronischen Kolitis 
ohne Tumorwachstum nachgewiesen werden. 
 
Die Administration von AOM bewirkt neben der Initiierung des Tumorwachstums 
auch die Apoptose der Kolonepithelzellen. Resultat dieser gestörten epithelialen 
Barrierefunktion ist eine erhöhte bakterielle Translokation in die Kolonschleimhaut 
[11]. Bedingt durch diese bakterielle Fehlbesiedlung kommt es zu einer gesteigerten 
intestinalen Entzündungsreaktion und der Infiltration von proinflammatorischen 
Makrophagen und T-Zellen, welche nachhaltig das Tumorwachstum unterstützen. 
 
 
 
 
Vielmehr deuten unsere Daten daraufhin, dass die Infiltration von 
Entzündungszellen ins Tumormilieu eine entscheidende Rolle in der Regulation des 
Tumorwachstums darstellt. Dieser Effekt beruht in unseren Beobachtungen auf der 
Tumor-Immunosurveillance durch zytotoxische T-Zellen. CD8+ T-Zellen besitzen die 
Möglichkeit Tumorepithelzellen zur Apoptose zu bringen indem E-Cadherin - ein 
Abb. 11: Schematische Charakteristik des Tumorwachstums in 
Abwesenheit von IL-21 im Vergleich zu einem IL-21 reichen 
Tumormilieu [12]. 
 
. 
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CD103 Ligand - gebunden wird. Die zytotoxische Kapazität wurde vorranging durch 
eine erhöhte Granzyme B Sekretion CD8/CD103+ zytotoxischer T-Zellen, in IL-21-/- 
Mäusen, vermittelt. Eine hohe IFN-γ Konzentration in Abwesenheit von IL-21 im 
Tumormilieu ermöglicht die Reifung und Infiltration von zytotoxischen CD8+ T-
Zellen und erhöht deren Vorkommen [13]. Unter Blockade von IFN-γ wird die 
Tumorregulation teilweise inhibiert und führte zu einem deutlichen Anstieg der 
Tumoranzahl in IL.21-/- Mäusen. Die erhöhte IFN-γ Produktion sorgt in IL-21 
defizienten Mäusen somit sowohl für die Entwicklung einer chronischen Kolitis als 
auch für eine verbesserte Tumorabwehr.  
Der Zusammenhang von IFN-γ und tumorbekämpfender Immunität konnte bereits 
bei verschiedenen experimentellen Tiermodellen und humanen Tumorentitäten 
beschrieben werden und bedingt weiteren Untersuchungen [14], [15], [16]. 
 
Zusammenfassend konnten wir nachweisen, dass IL-21 die Fähigkeit besitzt das 
Tumormilieu und die Tumor-immunosurveillance, im experimentellen Tiermodell, 
nachhaltig zu beeinflussen. 
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Interleukin 21 controls tumour growth and tumour
immunosurveillance in colitis-associated
tumorigenesis in mice
Dominik Jauch, Maria Martin, Gabriela Schiechl, Rebecca Kesselring,
Hans Ju¨rgen Schlitt, Edward K Geissler, Stefan Fichtner-Feigl
ABSTRACT
Background and aims Colitis-associated tumorigenesis
is a balance between proliferation of tumour cells and
tumour immunosurveillance. The role of T-helper-cell-
derived cytokines in tumour growth is not fully
understood. In this study the authors investigated the
inﬂuence of interleukin (IL) 21 on intestinal
tumorigenesis.
Methods Chronic colitis was induced in IL-21/ and
littermate control wild-type mice with three cycles of
1.5% dextran sulphate sodium (DSS) over 7 days
followed by 7 days of drinking water. Mice received an
azoxymethane injection on day 0 of DSS-colitis to induce
tumorigenesis. Immunohistochemistry was performed on
inﬂamed and tumour-bearing areas of colons. Cytokine
expression of isolated colonic CD4 T cells was
determined by ELISA. Cytotoxic capacity of isolated
colonic CD8 T cells targeting tumour cells was evaluated
by ﬂow cytometry and quantitative cytotoxicity assay.
Apoptosis of tumour cells was determined by TUNEL
assay of colonic sections.
Results Increasing expression of IL-21 was observed in
chronic colitis, which showed functional importance,
since IL-21 deﬁciency prevented chronic DSS-colitis
development. Further, in the absence of IL-21,
signiﬁcantly fewer tumour nodules were detected,
despite a similar extent of intestinal inﬂammation. In
wild-type mice, 8.661.9 tumour nodules were found
compared with 1.061.2 in IL-21-deﬁcient mice. In
tumour-bearing IL-21-deﬁcient mice, intestinal
inﬂammation was restored and partly dependent on
interferon (IFN)-g, whereas the inﬂammation in wild-type
mice showed high IL-17A concentrations. In these rare
tumours in IL-21-deﬁcient mice, tumour cell proliferation
(Ki-67) was decreased, while cell apoptosis was
increased, compared with wild-type mice. Increased
IFNg expression in tumour-bearing IL-21-deﬁcient mice
led to increased tumour immunosurveillance mediated by
cytotoxic CD8CD103 T cells targeting E-cadherin+
colonic tumour cells and therefore limited tumour
growth.
Conclusion These results indicate that IL-21
orchestrates colitis-associated tumorigenesis, leading to
the hypothesis that high IFNg and low IL-17A expression
reduces tumour cell proliferation and increases tumour
immunosurveillance.
INTRODUCTION
Long-lasting inﬂammatory bowel disease is accom-
panied by an increased risk of colorectal adenocar-
cinoma development.1e4 Based on information
obtained from a variety of animal studies, it is
obvious that the presence of chronic inﬂammation
provides a milieu that favours tumour cell prolifer-
ation. For instance, molecules that mediate or regu-
late proinﬂammatory innate immune signalling have
been shown to inﬂuence the local milieu during
colitis-associated tumour growth.5e14 One of the
key features of cells of the innate immune system
during colonic tumour development is the produc-
tion of cytokines that induce antigen-driven differ-
entiation of the adaptive immune system.15
Therefore the role of adaptive immunity in estab-
lishing the local cytokine milieu during colitis-
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Signiﬁcance of this study
What is already known about this subject?
< Chronic inﬂammation supports tumour growth.
< Tumour immunosurveillance can suppress
tumour growth.
< IL-21 can tip the balance between Th1 and Th17
differentiation.
< IL-21-deﬁcient mice are protected from acute
intestinal inﬂammation.
What are the new ﬁndings?
< Intestinal tumour growth is reduced in the
absence of IL-21 and this reduction is not due
to ameliorated colitis.
< IL-21 is necessary to establish a tumour-
supportive colonic micro milieu.
< In the absence of IL-21, colonic inﬂammation is
driven by IFNg which leads to increased tumour
immunosurveillance.
< Tumour immunosurveillance is mediated by
CD8CD103 T cells targeting E cadherin+ trans-
formed epithelial cells.
How might it impact on clinical practice in the
foreseeable future?
< Inﬂammatory inﬁltrates can be detected in
a broad variety of tumours and their metastases.
Understanding the inﬂammatory inﬁltrate char-
acterising the tumour microenvironment and its
effect on tumour immunosurveillance will help to
establish new treatment options in cancer
treatment. Targeting IL-21 is a potential target
for limiting tumour growth and increasing
tumour immunosurveillance in colitis-associated
tumour growth.
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associated tumour growth is not yet understood. In particular,
adaptive Th1 and Th17 cells have the capacity to inﬂuence the
local cytokine milieu in the colon, polarising the immune response
towards intestinal inﬂammation. IL-21 is a particularly interesting
cytokine to study in this respect because it affects the develop-
ment of naïve Tcells into Th1 or Th17 cells.15 Themain sources of
IL-21 under autoinﬂammatory conditions are NK cells and acti-
vated CD4 Tcells.
In the present study, we aimed to examine the importance of
IL-21 in the development of chronic intestinal inﬂammation as it
relates to tumour growth. Further analyses focused on the
importance of tumour immunosurveillance mediated by cyto-
toxic CD8 T cells and its dependency on the local cytokine
milieu, which is inﬂuenced by the presence of IL-21 during
chronic intestinal inﬂammation with tumour growth. Results
from our study suggest that IL-21 is essential for the generation
of a tumour-proliferative cytokine milieu and for the control of
tumour immunosurveillance, both of which are key aspects of
colitis-associated tumour growth.
METHODS
Mice
Speciﬁc pathogen-free IL-21/ (B6;129S5) and littermate control
wild-type mice (2e4 months old) were housed in the animal
facility at the University of Regensburg. IL-21/ B6;129S5 mice
were initially obtained from the Mutant Mouse Regional
Resource Center (University of California Davis). For transfer
colitis, IL-21/ mice and littermate controls were back-crossed
on to a C57BL/6 background. Animal use was approved by the
laboratory animal care guidelines of theUniversity of Regensburg.
Induction of colitis
Chronic dextran sulphate sodium (DSS)-colitis was induced by
three cycles of 1.5% DSS in drinking water for 1 week followed
by normal drinking water for 1 week. Colitis-associated tumor-
igenesis was induced by intraperitoneal injection of a single dose
of azoxymethane (AOM) (10 mg/kg; Sigma Aldrich, St Louis,
Missouri, USA) on day 0, followed by chronic DSS-colitis.
Cell isolation and cytokine measurement
Lamina propria mononuclear cells were isolated from colonic
tissues as previously described.16 17 CD4 cells were isolated by
magnetic bead sorting (Miltenyi Biotec, Bergisch Gladbach,
Germany) and cultured for 48 h under stimulation with plate-
bound antibody to CD3 (10 mg/ml) and soluble antibody to
CD28 (1 mg/ml) (BD Biosciences, San Jose, California, USA).
Cytokine concentrations were measured using ELISA kits,
according to the manufacturer ’s instructions (BD Biosciences,
San Jose, California, USA).
Immunohistochemistry
Sections were incubated with antibodies to Ki-67 (Dako,
Hamburg, Germany), Foxp3 (Abcam, Cambridge, UK), b-catenin
(Cell Signaling Technology, Danvers, Massachusetts, USA) and
E-cadherin (Cell Signaling Technology). TUNEL assay was
performed according to the manufacturer ’s (Roche, Mannheim,
Germany) protocol. For calculation of the extent of inﬂamma-
tion, H&E sections were examined by investigators blinded to
the experimental protocol and according to a previously
published scoring system.18
CTL assays
CTL assays (cytotoxic T-lymphocyte assay) were performed using
CD8 cells isolated from DSS-treated, tumour-bearing mice.
Isolated CD8 cells were co-incubated in vitro with either CT-26
cells or E-cadherin-transfected CT-26 cells (53104 cells). Cytolytic
activity was determined by CellTiter-Glo Luminescent Cell
Viability Assay (Promega, Madison, Wisconsin, USA). Performing
a cytotoxicity assay with CD8 T cells obtained from B6;129S5
mice using allogeneic CT-26 cells resulted in a higher baseline level;
however, the relative increase in cytotoxicity between treatment
groups, compared with baseline levels, remained quite stable.
Statistical analysis
For calculation of differences in histology score and proliferation
index, a KruskaleWallis test with Dunn’s multiple comparison
test was used. For calculation of differences in the number of
tumour nodules and cytokine concentrations, a two-way anal-
ysis of variance test with Bonferroni post-test was used. A value
of p<0.05 was considered signiﬁcant.
RESULTS
IL-21 is upregulated in chronic intestinal inﬂammation
IL-21 is a key effector cytokine for acute experimental colitis.19 In
our studies, we began to dissect the importance of IL-21 in the
development of chronic intestinal inﬂammation and the related
long-term complication of colonic tumour growth by ﬁrst inves-
tigating chronic colitis without tumour growth. We found that
increasing amounts of IL-21 are detectable during the course of
chronic colitis induced by DSS or 2, 4, 6-trinitrobenzenesulfonic
acid (TNBS) in wild-type mice, or by transfer of naïve T cells to
Rag1/ mice (online supplementary ﬁgure S1A,B).
IL-21-deﬁcient mice are protected against the development of
chronic DSS-colitis
After DSS administration to wild-type mice, we observed severe
chronic colitis. However, IL-21-deﬁcient mice were protected from
this type of inﬂammation (ﬁgure 1A). Further, on day 42 we found
a dramatic loss of colonic crypts and a signiﬁcant reduction in
goblet cell numbers in wild-type mice. In contrast, the morphology
and architecture of colonic tissue obtained from IL-21-deﬁcient
mice treated with DSS remained mostly intact (ﬁgure 1B).
Notably, general cellular proliferation measured by Ki-67 staining
within intestinal tissue was signiﬁcantly decreased after DSS
treatment in IL-21-deﬁcient mice (online supplementary ﬁgure S2).
We further determined the expression levels of IL-17A and
IFNg on day 42 of chronic DSS-colitis induction. As shown in
ﬁgure 1C, isolated CD4 cells from mesenteric lymph nodes of IL-
21-deﬁcient mice produced signiﬁcantly less IL-17A and IFNg
than wild-type animals. Similar ﬁndings were obtained in the
cell transfer colitis model (online supplementary ﬁgure S3). A
potential role for IL-17A and low IFNg in an ‘IL-21-mediated’
tumour-promoting effect was then considered.
Indeed, previous reports suggest that IL-21 can modulate the
balance between Th17 cells and Foxp3+ Treg.20 We did not
observe any difference in the distribution of Foxp3+ Treg on day
42 after DSS treatment initiation in wild-type versus IL-
21-deﬁcient mice (online supplementary ﬁgure S4). This obser-
vation is in contrast with data obtained from mice with acute
DSS-colitis (online supplementary ﬁgure S5). Similar changes
were obtained via ﬂow cytometric analysis examining for CD4
Foxp3+ Treg isolated cells from the colon of wild-type and IL-
21-deﬁcient mice (data not shown).
Tumour growth during chronic DSS-colitis is dependent on the
presence of IL-21
We next combined chronic DSS-colitis with an initial intraper-
itoneal administration of the carcinogenic substance AOM. We
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found that wild-type mice displayed an average of eight tumour
nodules per colon on day 42, whereas there was only about one
in IL-21-deﬁcient mice (ﬁgure 2A).
H&E staining revealed that tumour nodules consisted mostly of
adenoma tissue, with low- to high-grade intraepithelial neoplasia
(ﬁgure 2B). Although the morphology of tumours from wild-type
and IL-21-deﬁcient mice was similar, the diameter of tumours from
IL-21-deﬁcient mice was 30e40% less. Consistent with this
observation, Ki-67 staining revealed a lower cell proliferation rate in
tumours derived from IL-21-deﬁcient mice (ﬁgure 2C). Examination
of transformed epithelial cells revealed an intracellular and nuclear
expression pattern of b-catenin in tumour cells in wild-type and IL-
21-deﬁcient mice, whereas non-tumorous epithelial cells showed
weak cell membrane staining of b-catenin (ﬁgure 2D). To rule out
the possibility that the decreased tumour burden in IL-21-deﬁcient
mice on day 42 was because these mice exhibit less severe colitis
during the early course of the disease, we observed wild-type and
IL-21-deﬁcient mice until day 84 after the initiation of the model.
As shown in ﬁgure 2E, wild-type mice had developed an average of
nine tumour nodules on day 42 and an average of almost 20
tumour nodules on day 84. IL-21-deﬁcient mice showed hardly any
tumour burden on either day 42 or day 84, despite the fact that
chronic colitis lasted until day 84. This experiment demonstrates
that, despite chronic colitis, starting between days 21 and 28, IL-
21-deﬁcient mice are largely protected from tumorigenesis.
Tumour growth restores inﬂammatory signs in IL-21-deﬁcient
mice
Initially, we hypothesised that the reason for reduced tumour
formation in IL-21-deﬁcient mice would be reduced intestinal
inﬂammation. However, we found that the inﬂammation was
similar in wild-type and IL-21-deﬁcient mice on day 42 of
chronic DSS-colitis and AOM-induced tumour growth (ﬁgure
3A). It is worth noting that this restoration of intestinal
inﬂammation in IL-21-deﬁcient mice with AOM-induced
tumour growth was observed despite the use of a similar
approach for inducing the underlying chronic DSS-colitis (as
shown in ﬁgure 2), with the exception of not administering
AOM.
High IFNg expression in IL-21-deﬁcient mice with intestinal
tumorigenesis
To further elucidate the inﬂammatory milieu associated with
intestinal tumour growth with regard to IL-21 deﬁciency, we
determined cytokine expression in inﬂamed areas of colitis and
tumour-bearing areas. Figure 3b shows a signiﬁcant decrease in
IL-17A production on day 42 in tumour-bearing IL-21-deﬁcient
mice compared with results in wild-type mice. However, IFNg
expression during chronic DSS-colitis with AOM-induced
tumour growth showed the opposite: in the presence of
tumours, an increase in IFNg production was detected in IL-
21-deﬁcient mice. These results suggest that the presence of
AOM-induced tumours resulted in a change in the local cytokine
milieu, and that a high concentration of IFNg expression in IL-
21-deﬁcient mice does not support tumour growth to the extent
seen in an IL-17A-dominated micro milieu in wild-type mice.
We further investigated the expression pattern of IL-6 and IL-
22, cytokines that are both potentially proproliferative and
antiapoptotic for intestinal epithelial cells. There were no
changes in IL-6 or IL-22 production on day 42 (ﬁgure 3B). In
Figure 1 Interleukin (IL)-21-deﬁcient
mice are protected from chronic
dextran sulphate sodium (DSS)-colitis.
(A) H&E staining of representative colon
sections and histology score on day 42
of chronic DSS-colitis. Data shown are
mean values 6 SEM and derived from
at least 10 mice per group. Individual
points represent one mouse. *p#0.05.
(B) Alcian blue/periodic acid Schiff
(PAS) staining of representative colon
sections on day 42 of chronic DSS-
colitis. (C) IL-17A and interferon (IFN)-g
expression on day 42 of chronic DSS-
colitis. CD4 cells were extracted from
mesenteric lymph nodes and stimulated
for 48 h. Cytokine concentrations were
determined in culture supernatants by
ELISA. Data shown are mean values 6
SEM, derived from at least ﬁve mice per
group. *p#0.05. KO, knock-out; WT,
wild-type.
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addition, we determined the distribution of follicular helper CD4
T cells in mesenteric lymph nodes on day 35 of chronic DSS-
colitis with AOM-induced tumour formation. We found no
changes in the number of these cells (as determined by ﬂow
cytometry for CD4CD44highPD1+CXCR5high cells) in wild-type
or IL-21-deﬁcient mice (online supplementary ﬁgure S6). Further,
we did not observe any differences in architecture of spleens and
mesenteric lymph nodes.
As tumour-bearing IL-21-deﬁcient mice showed an unex-
pected change in cytokine production on day 42, we determined
the expression of IL-17A and IFNg during the early phase of
chronic DSS-colitis with AOM-induced tumour transformation
of colonic epithelial cells. IL-17A was only detectable at low
concentrations on day 7 and day 21 in IL-21-deﬁcient mice.
However, IFNg showed a signiﬁcant increase on day 21 in IL-
21-deﬁcient mice with tumour growth (ﬁgure 3C). These data
indicate that the cytokine switch occurs during the transition
phase from acute to chronic intestinal inﬂammation after
AOM-induced tumour transformation.
To investigate whether changes in histological architecture of
colons from wild-type mice or IL-21-deﬁcient mice during
chronic DSS-colitis with AOM-induced tumorigenesis occur
during the transition phase from acute to chronic colitis, we
carried out a time course experiment to assess histological
scoring on a weekly interval. We found that the onset of
increased colitis in IL-21-deﬁcient mice was on day 21 and
further increased until day 28 (ﬁgure 3D). Therefore the extent
of inﬂammation changes in accordance with the increase in
IFNg production in IL-21-deﬁcient mice during chronic
DSS-colitis with AOM-induced tumorigenesis.
An adaptive immune response characterised by the presence
of IL-17A or IFNg is preceded by the production of IL-23 or IL-
12, respectively. Therefore we determined the production of
these two cytokines by colonic CD11b cells during the transi-
tion phase of chronic DSS-colitis with AOM-induced tumori-
genesis. We found that IL-23 was upregulated in wild-type mice,
whereas IL-12p70 was greatly increased in IL-21-deﬁcient mice
(ﬁgure 3E). We hypothesised that this change in cytokine
production may be based on an epithelial-derived factor that is
stimulating antigen-presenting cells to produce either IL-23 or
IL-12. We harvested colonic epithelial cells on day 21 from either
wild-type or IL-21-deﬁcient mice and incubated naive CD11b
cells with lysates of these epithelial cells. Interestingly, we found
that lysates obtained from IL-21-deﬁcient mice were able to
Figure 2 Tumour number is decreased in the absence of interleukin (IL0-21. (A) Number of tumour nodules on day 42 of chronic dextran sulphate
sodium (DSS)-colitis with azoxymethane (AOM)-induced tumour growth. Data shown are mean values 6 SEM, derived from at least 10 mice per
group. Individual points represent one mouse. *p#0.05. (B) H&E staining in representative tumour areas of colon sections and tumour size on day 42
of chronic DSS-colitis with AOM-induced tumour growth. Measurements of tumour nodules refer to diameter and were made using a digitally obtained
image of the whole tissue section. Evaluation was performed using the Mirax Viewer software (Carl Zeiss AG, Germany). (C) Ki-67 staining of
representative tumour areas of colon sections and proliferation score on day 42 of chronic DSS-colitis with AOM-induced tumour growth. Data shown
are mean values 6 SEM, derived from at least 10 mice per group. Individual points represent one mouse. *p#0.05. (D) b-Catenin staining of
representative tumour areas of colon sections on day 42 of chronic DSS-colitis with AOM-induced tumour growth. (E) Number of tumour nodules on
day 42 and 84 of chronic DSS-colitis with AOM-induced tumour growth. Data shown are mean values6 SEM, derived from at least 10 mice per group.
Individual points represent one mouse. *p#0.05. HPF, high power ﬁeld; KO, knock-out; WT, wild-type.
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induce IL-12p70 production from either wild-type or IL-
21-deﬁcient CD11b cells (online supplementary ﬁgure S7A). We
also generated conditioned media from complete colon tissue,
isolated intestinal epithelial cells, lamina propria CD3 T cells,
and F4/80+ macrophages obtained from wild-type and IL-
21-deﬁcient mice on day 21 of DSS-colitis with AOM-induced
tumorigenesis. Naive CD11b cells were then cultured in condi-
tioned medium, and IL-12p70 production was determined. We
found that only conditioned medium from colon tissue or
isolated intestinal epithelial cells from IL-21-deﬁcient mice were
able to induce an increase in IL-12p70 production (online
supplementary ﬁgure S7B). These changes in inﬂammatory
response are also reﬂected in weight curves of wild-type and IL-
21-deﬁcient mice during chronic DSS-colitis with or without
AOM-induced tumorigenesis (online supplementary ﬁgure S8).
This set of data strengthens the hypothesis that epithelial-
derived factors are at least partly responsible for polarisation of
the adaptive immune response during chronic DSS-colitis with
AOM-induced tumorigenesis.
IFNg induces inﬂammation and tumour control in IL-21-deﬁcient
mice
Further analysis was performed to determine the role of IFNg
during chronic intestinal inﬂammation and tumour growth. For
this purpose, DSS-colitis with initial AOM injection was estab-
lished and combined with IFNg antibody administration twice
weekly starting on day 14. We found that inhibition of IFNg did
not affect chronic colitis in wild-type mice; however, it signiﬁcantly
reduced colitis in IL-21-deﬁcient mice (ﬁgure 4A). Furthermore,
antibody interference with IFNg resulted in an increase in tumour
number in IL-21-deﬁcient mice compared with IL-21-deﬁcient mice
receiving control IgG (ﬁgure 4B). Our results indicate that IFNg at
least partly mediates intestinal inﬂammation in IL-21-deﬁcient
mice with chronic DSS-colitis and AOM-induced tumour growth.
Figure 3 Restored inﬂammation in interleukin (IL)-21-deﬁcient mice with chronic dextran sulphate sodium (DSS)-colitis and tumorigenesis. (A) H&E
staining of representative inﬂammatory areas of colon sections and histology score on day 42 of chronic DSS-colitis with azoxymethane (AOM)-
induced tumour growth. Data shown are mean values 6 SEM, derived from at least 10 mice per group. Individual points represent one mouse.
*p#0.05. (B) IL-17A, interferon (IFN)-g, IL-6 and IL-22 expression on day 42 of chronic DSS-colitis with AOM-induced tumour growth. CD4 or CD11b
cells were extracted from the lamina propria of inﬂamed and tumour-bearing areas, and then stimulated for 48 h. Cytokine concentrations were
determined in culture supernatants by ELISA. Data shown are mean values 6 SEM, derived from at least ﬁve mice per group. *p#0.05. (C) IL-17A and
IFNg expression on day 7 and day 21 of chronic DSS-colitis with AOM-induced tumour growth. CD4 cells were extracted from the lamina propria from
inﬂamed and tumour-bearing areas and stimulated for 48 h. Cytokine concentrations were determined in culture supernatants by ELISA. Data shown
are mean values6 SEM, derived from at least ﬁve mice per group. *p#0.05. (D) Histology score on days 14, 21, 28 and 35 of chronic DSS-colitis with
AOM-induced tumour growth. Data shown are mean values 6 SEM, derived from at least seven mice per group. Individual points represent one
mouse. (E) IL-23 and IL-12p70 expression on day 7 and day 21 of chronic DSS-colitis with AOM-induced tumour growth. CD11b cells were extracted
from the lamina propria and stimulated for 48 h. Cytokine concentrations were determined in culture supernatants by ELISA. Data shown are mean
values 6 SEM, derived from at least ﬁve mice per group. *p#0.05. KO, knock-out; WT, wild-type.
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CD8 T cells control tumour growth
Previous work has shown that IFNg is able to promote an
antitumour response, which can be mediated by CD8 cytotoxic
Tcells. To test for a potential role of CD8 Tcells in this model, we
administered antibody to CD8 weekly starting on day 14 of
chronic DSS-colitis with AOM-induced tumour growth.
Although CD8 antibody treatment reduced the number of
circulating CD8 T cells by 85% (data not shown), this depletion
did not inﬂuence the level of inﬂammation of chronic DSS-colitis
with AOM-induced tumour growth (ﬁgure 5A). The number of
tumour nodules per mouse and the diameter increased signiﬁ-
cantly with CD8 Tcell depletion in wild-type and IL-21-deﬁcient
mice (ﬁgure 5B and C). To determine if NKT cells or NK cells
might be exerting cytotoxic effects in terms of tumour immu-
nosurveillance during chronic DSS-colitis with AOM-induced
tumour growth, we depleted these cell types by administering
antibody against either CD1 or asialo GM1 (starting on day 14),
respectively. As shown in online supplementary ﬁgure S9, neither
depletion of NKT cells nor depletion of NK cells resulted in
a change in tumour burden in wild-type and IL-21-deﬁcient mice.
Cytotoxicity against tumour epithelial cells increases in IL-21-
deﬁcient mice
Previous studies show that cytotoxic CD8 T cells speciﬁc for
tumour cells limit tumour growth (immunosurveillance), as
CD8 T cells bearing CD103 (aEb7) can bind E-cadherin
on tumour cells.21e23 Tumour cells from wild-type and IL-
21-deﬁcient mice have a similar E-cadherin expression pattern
during chronic DSS-colitis with AOM-induced tumour growth
(ﬁgure 6A). Therefore the potential target cell for cytotoxic CD8
T cells was available in either wild-type or IL-21-deﬁcient mice.
However, as shown in ﬁgure 6B, wild-type mice with AOM-
induced tumour growth had fewer CD8CD103 Tcells on day 28
than similarly treated IL-21-deﬁcient mice.
The cytotoxic potential of CD8 T cells was demonstrated by
the extent of granzyme B and perforin expression on day 28.24 25
This evaluation time point was chosen in order to investigate
the cytotoxic potential of CD8 T cells at the time of early
tumour immunoediting. CD8 T cells from IL-21-deﬁcient mice
showed a signiﬁcant increase in granzyme B and a slight increase
in perforin expression. Cytotoxic effects of CD8 T cells isolated
from colon tumours against (allogeneic) CT-26 colon tumour
cells (not expressing E-cadherin) and CT-26 cells transfected
with an E-cadherin-expressing plasmid were tested. CD8 T cells
from wild-type mice exhibited only minimal cytotoxicity
against untransfected CT-26 cells, although they did exhibit
substantial cytotoxicity against transfected E-cadherin-
expressing CT-26 cells (ﬁgure 6C). CD8 Tcells isolated from IL-
21-deﬁcient mice showed a relatively enhanced cytotoxic effect
against E-cadherin-expressing CT-26 cells. These results are
consistent with our ﬁnding that tumours from IL-21-deﬁcient,
versus wild-type mice, showed a signiﬁcant increase in apoptotic
cells as determined by TUNEL staining (ﬁgure 6D). Finally, we
examined the dependence of this cytotoxic effect on IFNg and
evaluated the presence of cytotoxic CD8CD103 T cells in the
colon after IFNg antibody treatment. The inhibition of IFNg
resulted in a signiﬁcant reduction of CD8CD103 T cells in the
colon of IL-21-deﬁcient mice (ﬁgure 6E). Therefore we could
demonstrate that the presence of cytotoxic CD8CD103 Tcells in
IL-21-deﬁcient mice was dependent on IFNg. Together, these
data show that, while cytotoxic CD8CD103 T cells are poten-
tially capable of exerting immunosurveillance functions against
tumour cells, this function is probably controlled by the
cytokine milieu in the colon.
Figure 4 Interferon (INF)g regulates
inﬂammation and tumour growth in the
absence of interleukin (IL)-21. (A) H&E
staining of representative colon
sections of inﬂamed areas and histology
score on day 42 of chronic dextran
sulphate sodium (DSS)-colitis with
tumour growth after inhibition of IFNg.
Inhibition of IFNg started on day 14.
Data shown are mean values 6 SEM,
derived from at least 10 mice per group.
Individual points represent one mouse.
*p#0.05. (B) Number of tumour
nodules on day 42 of chronic DSS-
colitis with azoxymethane-induced
tumour growth after inhibition of IFNg.
Inhibition of IFNg was started on day
14. Data shown are mean values 6
SEM, derived from at least 10 mice per
group. Individual points represent one
mouse. *p#0.05. KO, knock-out; WT,
wild-type.
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DISCUSSION
The aetiology of inﬂammatory bowel disease, consisting
primarily of Crohn’s disease and ulcerative colitis, is not fully
understood.26e28 One long-term consequence of an altered
immune homoeostasis at the mucosal surface is development of
colorectal cancer. In this article, we demonstrate that IL-21 is an
important factor in tumour growth and immunosurveillance
during colitis-associated tumorigenesis. In this regard, we show
that IL-21 is necessary for the establishment of a tumour-
supportive micro milieu in the colon, which is characterised by
the presence of the cytokine IL-17A and limited tumour
immunosurveillance through reduced concentrations and func-
tional capacity of cytotoxic CD8CD103 T cells.
Although an important effect of IL-21 on the development of
chronic intestinal inﬂammation was expected, the situation
changed when tumour growth was accompanied by robust
intestinal inﬂammation even in the absence of IL-21; this
inﬂammation was partly mediated through IFNg produced by
CD4 Tcells. It was obvious that the intestinal inﬂammation and
tumour growth were able to interact in both directions. This
important link between inﬂammation and cancer has been
known for centuries.29 30 The inﬂammation orchestrates the
microenvironment around tumours, and the tissue distribution
of T cell subsets in human cancers clearly shows that a broad
variety of solid tumours are associated with an increase in
tumour microenvironmental Th17 cells.31 32 In our study,
tumour growth in wild-type mice was associated with high
production of IL-17A by inﬁltrating CD4 T cells and a reduced
concentration of IFNg, mimicking the cytokine pattern
observed in a variety of human solid tumours.33e36 Importantly,
our results indicate that the balance between these two polar-
ised T cell subsets is tipped by IL-21.
It is widely accepted that tumour cell proliferation can be
mediated through Tcells after stimulation with tumour antigen
that is presented by tumour-associated macrophage cells,
a cellular interaction known to induce IL-17 expression.33 Our
results indicate that IL-21 has a major role in the generation of
a proliferative, IL-17A-based, tumour microenvironment. We
have demonstrated that, in the absence of IL-21, the inﬂam-
matory response is characterised by high IFNg concentration,
not by high IL-17A concentration. Therefore one can assume
that the reduction in tumour number in the absence of IL-21 is
not based on the existence of inﬂammation, but rather on the
speciﬁc characteristics of the tumour microenvironment. This
change in tumour microenvironment is in concordance with
ﬁndings of previous reports in which IL-21 could inhibit IFNg
expression when IL-21 was present at the time of naïve CD4 T
cell priming under Th1 conditions.37 In addition to our ﬁndings
in mice, it has been shown that human biopsy specimens
obtained from patients with Crohn’s disease produce less IFNg
when IL-21 is blocked in an ex vivo culture.38 This set of data
published by Monteleone et al does not necessarily contradict
our ﬁndings, as we have also found that IFNg expression is very
low in IL-21-deﬁcient mice in the absence of tumours. Further-
more, Sarra et al demonstrated that, in the human gut, IL-21 is
mainly produced by CD4 T cells co-expressing IFNg.39 There-
fore, a likely explanation for reduced IFNg production by ex vivo
culture of biopsy specimens from patients with Crohn’s disease
is that the inhibition of IL-21 concomitantly blocks the
production of IFNg from the same cell.
It is well accepted that IL-21 plays a pathogenic role in
intestinal inﬂammation. However, this effect has not been seen
in a situation when tumour induction was incited by AOM. In
our work, we show that epithelial cell lysates and conditioned
Figure 5 CD8 T cells control tumour
growth. (A) H&E staining of
representative colon sections of
inﬂamed area and histology score on
day 42 of chronic dextran sulphate
sodium (DSS)-colitis with tumour
growth, after deletion of CD8 T cells.
CD8 T cell deletion was started on day
14. Data shown are mean values 6
SEM, derived from at least 10 mice per
group. Individual points represent one
mouse. *p#0.05. (B) Number of
tumour nodules on day 42 of chronic
DSS-colitis with azoxymethane (AOM)-
induced tumour growth, after deletion
of CD8 T cells. CD8 T cell deletion was
started on day 14. Data shown are
mean values 6 SEM, derived from at
least 10 mice per group. Individual
points represent one mouse. *p#0.05.
(C) Diameter of tumour nodules on day
42 of chronic DSS-colitis with AOM-
induced tumours after deletion of CD8 T
cells. CD8 T cell deletion was started on
day 14. Measurements of tumour
nodules refer to diameter and were
made using a digitally obtained image
of the whole tissue section. Evaluation
was performed using Mirax Viewer
software (Carl Zeiss AG, Germany). KO,
knock-out; WT, wild-type.
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media obtained from isolated epithelial cells of IL-21-deﬁcient
mice after AOM administration are able to induce a strong Th1
response that is in turn mediating the colitis, albeit with
a different cytokine pattern of inﬂuence. We have not yet
elucidated the actual factor released by intestinal epithelial cells
to induce a Th1-polarised colonic microenvironment. One
potential candidate for the induction of IL-12 production by
CD11b cells with consecutive IFNg expression is IL-18, which
was initially described as IFNg-inducing factor. IL-18 is upre-
gulated in the intestinal mucosa of patients with inﬂammatory
bowel disease, and blockade of IL-18 reduces the extent of
intestinal inﬂammation induced by DSS.40 In accordance with
the hypothesis that IL-18 might initiate a tumour-suppressive
Th1-based microenvironment, recent work from Salcedo et al
has shown that IL-18-deﬁcient mice have a much higher tumour
burden than wild-type mice during chronic DSS-colitis with
AOM-induced tumour formation.7 However, additional research
is necessary to test this hypothesis.
In addition, inﬂammatory cells in the tumour microenviron-
ment may have an important role in initiating and maintaining
protective antitumour immunity by tumour immunoediting.
One such effect investigated in our study relates to the immu-
nosurveillance of AOM-induced tumours mediated by cytotoxic
cells. After excluding NK cells and NKT cells as possible cyto-
toxic effector cells, we could demonstrate that the capacity of
CD8 T cells to be immunosurveillant is inherent in their ability
to kill epithelial cell tumour lines bearing E-cadherin (a CD103
ligand) ex vivo. Notably, the presence of CD8CD103 cytotoxic T
cells was greatly increased in the absence of IL-21 and dependent
on IFNg. These results are consistent with facilitated binding of
antitumour CD8CD103 Tcells to E-cadherin-expressing tumour
cells.41 Moreover, under these conditions, killing is presumably
mediated by a granzyme B-dependent effect of CD8 cytotoxic T
cells, as this potent cytotoxic molecule was highly upregulated
in CD8 Tcells of IL-21-deﬁcient mice. The reason why a tumour
microenvironment with a high expression level of IFNg
promotes an antitumour response probably lies in the capacity
of IFNg to facilitate maturation of CD8 cytotoxic T cells.42 In
fact, IFNg has been associated with antitumour immunity and
its dependence on the adaptive immune system in a variety of
different tumour entities.43 44 Previous in vitro experiments have
shown that IL-21 can inﬂuence the proliferation of CD8 Tcells,
whereas the cytotoxic function is not compromised.45 46 In
addition, Hinrichs et al showed that antigen-induced acquisition
of effector CD8 T cell phenotype and function is suppressed by
the presence of IL-21.47 These facts are in accordance with data
presented in this article, since the number of CD8 T cells
remained stable regardless of the presence of IL-21. However, the
Figure 6 Tumour immunosurveillance increases in the absence of interleukin (IL)-21. (A) E-cadherin staining of representative tumour areas of colon
sections on day 42 of chronic dextran sulphate sodium (DSS)-colitis with azoxymethane (AOM)-induced tumour growth. (B) Flow cytometric
determination of CD8CD103, CD8granzyme B and CD8perforin cells in the colon on day 28 of chronic DSS-colitis with AOM-induced tumour growth.
Cells were extracted from the lamina propria on day 28 and stained with ﬂuorochrome-conjugated antibodies. (C) Cytotoxicity of CD8 T cells against
CT-26 cells or E-cadherin+ CT-26 cells. CD8 T cells were isolated from the colon on day 28 of chronic DSS-colitis with AOM-induced tumour growth
and co-cultured with CT-26 cells or E-cadherin+ CT-26 target cells. Cytotoxicity was measured after 24 h of cytolytic activity. (D) TUNEL assay of
representative tumour areas of colon sections on day 42 of chronic DSS-colitis with AOM-induced tumour growth. Data shown are mean values 6
SEM, derived from at least 10 mice per group. Individual points represent one mouse. *p#0.05. (E) Flow cytometric determination of CD8CD103 cells
in the colon of IL-21-deﬁcient mice on day 28 of chronic DSS-colitis with AOM-induced tumour growth after inhibition of interferon (IFN)g. Inhibition of
IFNg was started on day 14. Cells were extracted from the lamina propria on day 28 and stained with ﬂuorochrome-conjugated antibodies.
CTL, cytotoxic T-lymphocyte; HPF, high power ﬁeld; KO, knock-out; WT, wild-type.
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functional capacity of cytotoxic CD8 T cells was greatly
increased in the Th1-dominated environment present in IL-
21-deﬁcient mice with intestinal tumour induction.
Owing to the fact that on day 42 of chronic DSS-colitis with
AOM-induced tumour growth in IL-21-deﬁcient mice, the
tumour cell proliferation index is w10%, while the apoptotic
index is about 20%, we consider that these tumours may
undergo regression to some degree on day 42. Our experience
with colitis-associated tumorigenesis models shows that the rate
of tumour cell proliferation is highest at the time when tumours
start to become visible macroscopically and that tumour cell
cytotoxicity becomes apparent slightly later than the ﬁrst
appearance of macroscopic tumour nodules. Therefore this
timing difference is probably the explanation for the differences
seen between the proliferation index and apoptotic index.
In conclusion, we have demonstrated in this study that the
cytokine IL-21 is capable of inﬂuencing the development of chronic
intestinal inﬂammation. Importantly, our results show that IL-
21 is a key cytokine that tips the balance between a tumour-
proliferative and a tumour-suppressive microenvironment,
substantially inﬂuencing tumour growth.
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IL-21 is upregulated in chronic intestinal inflammation. (A) IL-21 mRNA expression of 
isolated colonic lamina propria mononuclear cells on indicated time points of chronic 
DSS-colitis, transfer colitis and chronic TNBS-colitis. IL-21 mRNA expression was 
determined by quantitative PCR analysis. Data shown are mean values ± SEM from 
at least five mice per group. *, p ≤0.05. (B) IL-21 expression in total colonic protein 
extracts on indicated time points of chronic DSS-colitis, transfer colitis and chronic 
TNBS-colitis. Cytokine concentrations were determined by ELISA. Data shown are 
mean values ± SEM from at least five mice per group. *, p ≤0.05. 
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Morphologic characteristics of DSS-colitis. Ki-67 staining of representative colon 
sections and proliferation score on day 42 of chronic DSS-colitis. Data shown are 
mean values ± SEM and derived from at least ten mice per group. Individual points 
represent one mouse. *P≤0.05.  
 
Due to the fact that IL-17A, in particular during an ongoing inflammatory response, is 
a potent inducer of cell proliferation, we determined the proliferation index on day 42 
of chronic DSS-colitis in wild type and IL-21-deficient mice. We distinguished 
between cell proliferation of colonic epithelial cells, intraepithelial lymphocytes and 
submucosal lymphocytes by Ki-67 staining. As shown in Figure S2, the proliferation 
of colonic epithelial cells as well as of intraepithelial lymphocytes was significantly 
increased in wild type mice compared to IL-21-deficient mice. In addition, there is a 
highly significant increase of proliferation of lymphocytes in the submucosal area in 
wildtype when compared to IL-21-deficient mice. 
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IL-21-deficient naïve T cells hardly induce intestinal inflammation in Rag1-/- mice. (A) 
H&E staining of representative colon sections on day 42 of transfer colitis. (B) Alcian 
blue/PAS staining of representative colon sections on day 42 of transfer colitis. (C) 
Ki-67 staining of representative colon sections on day 42 of transfer colitis.  (D) IL-
17A, IFN-γ, IL-17F, IL-22 expression on day 42 transfer colitis. CD4+ cells were 
extracted from mesenteric lymph nodes and stimulated for 48h. Cytokine 
concentrations were determined in culture supernatants by ELISA. Data shown are 
mean values ± SEM and derived from at least five mice per group. *, p ≤0.05. 
 
The transfer of IL-21-deficient naïve T cells resulted in a reduced extent of chronic 
inflammation, which was accompanied by a significant reduction of IL-17A, IFN-γ, IL-
17F, and IL-22 production when compared to Rag1-/- mice that received wildtype 
naïve T cells. 
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Foxp3+ Treg expression is similar on day 42 of chronic DSS-colitis when comparing 
wild-type mice and IL-21-deficient mice. Foxp3 staining of representative colon 
sections on day 42 of chronic DSS-colitis. Data shown are mean values ± SEM and 
derived from at least ten mice per group. Individual points represent one mouse.   
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Foxp3+ Treg are upregulated during acute DSS-colitis in IL-21-deficient mice. Foxp3 
staining of representative colon sections and colonic lymphoid follicles on day 7 of 
acute DSS-colitis. Data shown are mean values ± SEM and derived from at least ten 
mice per group. Individual points represent one mouse. *P≤0.05.   
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Figure S6
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Distribution of follicular helper CD4 T cells in mesenteric lymph nodes on day 35 of 
chronic DSS-colitis with AOM induced tumour formation. We could not detect 
changes in the number of TFH cells (as determined by flow cytometry for 
CD4+CD44highPD1+CXCR5high cells) in wild-type or IL-21-deficient mice. 
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(A) IL-12p70 production from isolated splenic naive CD11b+ cells of wild-type or IL-
21-deficient mice following the incubation with lysates from colonic epithelial cells 
obtained from wild-type or IL-21-deficient mice on day 21 of chronic DSS-colitis with 
AOM-induced tumour growth. Cytokine concentrations were determined in culture 
supernatants by ELISA. Data shown are mean values ± SEM, derived from at least 
five mice per group. *P≤0.05. 
(B) IL-12p70 production from isolated splenic naive CD11b+ cells of wild-type mice 
following the incubation with conditioned media from complete colon tissue, isolated 
intestinal epithelial cells, isolated lamina propria CD3+ cells and isolated lamina 
propria F4/80+ cells obtained from wild-type or IL-21-deficient mice on day 21 of 
chronic DSS-colitis with AOM-induced tumour growth. Cytokine concentrations were 
determined in culture supernatants by ELISA. Data shown are mean values ± SEM, 
derived from at least five mice per group. *P≤0.05. Conditioned medium was 
collected from cells incubated in serum-free medium for 24h and filtered through a 
0.22-mm filter.  
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Body weight of mice with chronic DSS-colitis with or without AOM-induced tumour 
growth. (A) Body weight as a percent of starting weight. Data shown are mean values 
± SEM and derived from at least six mice per group. 
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NKT cells or NK cells do not influence tumour growth. Number of tumour nodules on 
day 42 of chronic DSS-colitis with AOM-induced tumour growth, after deletion of NKT 
cells (anti-CD1-antibody) or NK cells (anti-asialo GM1- antibody). NKT or NK cell 
depletion was started on day 14. Data shown are mean values ± SEM, derived from 
5 mice per group. Individual points represent one mouse.  
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Colitis-associated cancer: the
dark side of inﬂammatory bowel
disease
Silvio Danese,1 Alberto Malesci,1,2 Stefania Vetrano1
The intrinsic connection between inﬂam-
mation and cancer promotion is well
established and is especially strong in
patients with colorectal cancer (CRC), the
second most common cause of cancer-
related death in Western countries.1 2
The administration of non-steroidal anti-
inﬂammatory drugs in controlled studies
reduces the incidence of colon cancer in
patients with familial adenoma polyposis,
conﬁrming the link between inﬂammation
and colon cancer.3 Several lines of evidence
indicate that chronic inﬂammation predis-
poses the tissue to cancer by inducing gene
mutation, inhibiting apoptosis or stimu-
lating angiogenesis and cell proliferation.
Patients with inﬂammatory bowel disease
(IBD) are at increased risk of developing
CRC and, in particular, an association
between IBD and the development of
colitis-associated cancer (CAC) has been
reported. Although the severity and extent
of disease and the duration of inﬂammation
seem to be major factors associated with
the development of CAC in patients with
IBD, the molecular determinants of this
link have only recently started to be eluci-
dated. Studies have highlighted the presence
of leucocyte inﬁltration and inﬂammatory
mediators in the tumour microenviron-
ment, indicating that immune cells are
major players in tumour promotion.2 4
Preclinical models of CAC are helping to
clarify the mechanisms underlying cancer-
related inﬂammation. The direct role of
the adaptive immune response in
promoting CAC is becoming more
evident.2 Although T cell responses fuel
the inﬂammatory process and orchestrate
the microenvironment surrounding
tumours by contributing to the prolifera-
tion, migration and survival of cancer
cells, activation of the adaptive immune
system also plays an important role in
inhibiting tumour growth and progression
through the recognition and rejection of
malignant cells, a process referred to as
immunosurveillance or immunoediting.5
On one hand, the aberrant immune
response predisposes tissues to cancer,
while on the other hand, the full activa-
tion of an effective adaptive immune
response is necessary for tumour eradica-
tion. Indeed, it is on the battle between
the protumour- and antitumour-
promoting immune cells that the fate of
the tissue depends. Among immune cells,
the Th1 helper T subset has long been
implicated in the inﬂammation that
underlies IBD; however, in more recent
years it has become apparent that Th1
cells are not the primary instigators.6 A
new subset that expresses a distinct set of
inﬂammatory regulators was identiﬁed
through their expression of the interleukin
17 (IL-17) family cytokines, of which
there are ﬁve family members (IL-17AeIL-
17F) that are termed the Th17 subset. The
Th17 subset is implicated as playing
a defensive role against extracellular
bacteria and also in the pathogenesis of
several autoimmune conditions. In
a physiological adaptive immune
response, the release of IL-17 leads to
secretion of cytokines and chemokines
that mobilise neutrophils indispensable
for pathogen clearance.7 Human studies
have reported that patients suffering from
IBD displayed high levels of IL-17-
producing Tcells in the intestinal mucosa,
which also produce interferon g (IFNg).8
Furthermore, elevated levels of IL-17A are
detected in the serum of patients with
active IBD. Human genetic studies and in
vivo studies further support the patho-
logical role of the IL-17 pathway in IBD
pathogenesis, but its contribution to colon
cancer is still controversial. Tumour-inﬁl-
trating Th17 cells have been observed in
multiple human cancer types.9 Th17 cell
activation and inﬁltration in the tumour
microenvironment appear to inhibit IL-12
transcription while enhancing IL-23 tran-
scription, thereby shifting the balance
from Th1 to Th17. Consequently, this
switch leads to a decreased production of
IFNg, which is the predominant Th1
cytokine that plays an important role for
CD4 T cell-mediated antitumour immu-
nity.
Recently, IL-21 has also been identiﬁed
as an IL-17-inducing cytokine. IL-21 is
produced mainly by CD4 Tcells, as well as
by natural killer T (NKT) cells, and exerts
pleiotropic functions on various immune
cells.7
Enhanced expression of IL-21 is detected
in biopsies of patients with IBD and in
colitic mice, and seems to trigger an
exacerbated inﬂammatory response, while
genetic deletion of IL-21 prevents intes-
tinal colitis.10
Although the IL-21 and IL-17 pathway
are involved in both the initiation and
perpetuation of intestinal inﬂammation, it
remains to be clariﬁed whether these
pathways can also be considered as trig-
gers for the development of CAC. In their
paper published in this issue of Gut, Jauch
et al demonstrate a key role for IL-21 in
supporting intestinal tumourigenesis, as it
induces a change in the local cytokine
milieu towards Th17 cytokines.11 In line
with previous data, the authors observe
that IL-21-deﬁcient mice develop an
attenuated chronic intestinal inﬂamma-
tion compared with wild-type mice that is
characterised by reduced levels of IL-17A
and IFNg, without any changes to the
regulatory T cells. In contrast, when the
chronic inﬂammation is associated with
a tumourigenic process, the absence of
IL-21 does not prevent the inﬂammatory
process as we may expect, but instead
induces a Th1 cytokine shift, reducing the
levels of IL-17A.
Although Jauch et al do not specify
whether the increased levels of IL-17A
correlate with a high presence of IL-17 T
cells in the mucosa, they demonstrate that
IL-21 can tip the balance between Th1 and
Th17 differentiation. Additionally, this
balance is a determinant for the promo-
tion of intestinal cancer. Indeed, the
absence of IL-21 correlates signiﬁcantly
with fewer tumour nodules, which are
characterised by a reduced diameter
compared with those observed in wild-
type mice. Intriguingly, the remarkable
reduction in tumour growth is not asso-
ciated with an ameliorated colitis in IL-21-
deﬁcient mice, but with an increased
production of IFNg that achieves tumour
immunosurveillance by enhancing the
levels of cytotoxic CD8CD103 T cells.
Evidence continues to suggest that the
unresolved chronic inﬂammation triggers
1Division of Gastroenterology, IRCCS Istituto Clinico
Humanitas, Rozzano, Milan, Italy; 2Department of
Translational Medicine, University of Milan, Milan
Correspondence to Dr Silvio Danese, IBD Center,
Division of Gastroenterology, Istituto Clinico Humanitas,
Via Manzoni 56, 20089 Rozzano, Milan, Italy;
sdanese@hotmail.com
Gut December 2011 Vol 60 No 12 1609
Commentary
36
the initiation and promotion of cancer;
studies that describe the kinetics of these
events are still lacking. In this work, the
authors demonstrated that the switch
from a Th1 to a Th17 cell cytokine proﬁle
that is induced by IL-21 coincides with the
transition phase from acute to chronic
intestinal inﬂammation, and inﬂuences
the tumour-supportive microenviron-
ment. Thus, these data support the
hypothesis that, in the course of acute
intestinal inﬂammation, the environment
triggers the differentiation of CD4 T cells
to a Th1 immune response. The Th1
cytokines such as IFNg then induce the
production of IL-21 and consequently of
IL-23, which leads to Th17-mediated
chronic inﬂammation. This sequence of
events is dependent upon the presence of
IL-21. Indeed, the absence of IL-21 reduces
the levels of IL-23, and upregulates the
production of IL-12, maintaining therefore
a Th1 cytokine proﬁle such as IFNg. The
high levels of IFNg promote an anti-
tumour response, enhancing the capacity
of cytotoxic CD8 T cells and thereby
negatively inﬂuencing tumour growth
(ﬁgure 1). Although this work shows that
IL-21 inﬂuences the production of epithe-
lial-derived factors involved in the polar-
isation of the adaptive immune response,
it remains unclear whether IL-21 interacts
with other cytokines in controlling this
switch. Thus, neutralisation of IL-21 could
be a target not only for the attenuation of
immune inﬂammatory response, but also
for colon cancer therapy. These ﬁndings
have relevance to human therapy, but
further studies are necessary. In particular,
studies in humans will be necessary, as it
is well known that animal models of IBD
and colon cancer have many limitations,
and only partially reﬂect the complexity
of human diseases.
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Figure 1 Function of interleukin 21 (IL-21) in a tumour-supportive microenviroment during colitis-
associated cancer. In the normal intestine, the physiological inﬂammation serves to resolve the
antigen insult that provokes the infection or damaged tissue. The differentiation of naı¨ve T cells into T
helper 1 (Th1) or Th17 is antigen dependent, and is necessary to prevent the spread of the infection.
The cytokine milieu inﬂuences the development of these lineages. IL-21 cytokine tips the balance
towards Th17 differentiation. When the adaptive immune response fails to resolve the inﬂammation,
as happens in patients with inﬂammatory bowel disease (IBD), the increased production of IL-21
coincides with the transition phase from acute to Th17-mediated chronic intestinal inﬂammation,
characterised by high levels of IL-17A. In addition, IL-21 reduces the production of interferon g (IFNg),
which exerts antitumour activity enhancing the capacity of cytotoxic CD8 T cells. Thus IL-21 on one
hand supports chronic inﬂammation and on the other hand reduces tumour immunosurveillance and
promotes a tumour-supportive microenvironment in the colon.
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Interleukin 21 impairs tumor immunosurveillance
of colitis-associated colorectal cancer
Rebecca Kesselring, Dominik Jauch and Stefan Fichtner-Feigl*
Laboratory of Chronic Immunopathology; Department of Surgery; University Medical Center Regensburg; Regensburg, Germany
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The pathogenesis of colitis-associated colorectal cancer is strongly influenced by immune cells, cytokines and other
immune mediators present in the inflamed colon. Current research has emerged that T helper cell associated cytokines
play a prominent role in tumor growth. In our recent manuscript we have revealed that the Th17 associated cytokine
IL-21 prominently influences tumor development and immunosurveillance of colitis-associated colorectal cancer.
Longstanding inflammatory bowel diseases
(IBD) such as ulcerative colitis (UC) and
Crohn disease (CD) have an increased risk
to develop colorectal cancer.1 This asso-
ciation of IBD with colorectal cancer was
first described by Crohn et al. in 1925.2
Chronic inflammation promotes carcino-
genesis by inducing gene mutations and
epigenetic alterations, alteration of the
expression of factors involved in carcino-
genesis (p53, APC, K-ras, Bcl-2, NFkB,
COX-2, DNA mismatch— or base-
excision repair proteins), releasing of
reactive oxygen and nitrogen species,
inhibiting apoptosis or stimulating angio-
genesis and cell proliferation. The role of
the immune system during the process of
cancer development is multifactorial and
complex. Whereas some immune cells are
able to elicit protumoral effects others
diminish tumor progression as part of the
antitumoral immune response. However,
this extensive network of tumor immune
responses is far from completely under-
stood. Among hematopoietic cells which
can regulate cancer pathogenesis T cells
play a prominent role. Thus, CD4+ T cells
as well as CD8+ T cells and regulatory
T cells can influence the tumor micro-
milieu. With this regard T cell subsets
especially Th17 cells seem to be a poten-
tial target for new immunotherapeutic
approaches to treat colitis-associated colo-
rectal cancer as these cells were shown to
have prominent functions in mucosal
immunity. Th17 cells are termed accord-
ing to their secretion of the cytokine IL-
17A and are a distinct proinflammatory
CD4 effector T-cell lineage.3 Besides the
secretion of IL-17A Th17 cells secrete the
cytokines IL-17F, IL-21 and IL-22. The
secretion of these Th17 cell-associated
cytokines leads to the induction of
chemokines, matrix metalloproteinases as
well as antimicrobial peptides in the
surrounding tissue, leading to inflam-
mation and recruitment of neutrophils
and macrophages, but less is known about
the function of these cytokines in cancer
development.
Among Th17-associated cytokines
IL-21 seems to represent an interesting
target for immunotherapeutic approaches
as IL-21 is able to tip the balance between
Th1 and Th17 cells.4 IL-21 is able to
impact both innate and adaptive immune
responses due to its ability to act on
multiple immune cells expressing the
IL-21 receptor like B cells, NK cells,
activated T cells, DCs, macrophages as
well as fibroblasts and epithelial cells.
Upon engagement of its receptor IL-21
signals through JAKs, STAT3 and ulti-
mately Bcl-6, Tcf7, Lef1, Blimp-1 and
c-Maf. Therewith IL-21 is able to influ-
ence the differentiation, cell fate, pro-
liferation and survival of diverse immune
cell subsets. As mentioned above IL-21
promotes the differentiation of Th17 cells
whereas it limits the development of Tregs
and effector CD8+ T cells. It has been
shown that IL-21 is overexpressed in the
gut of patients with UC and CD com-
pared with healthy controls5 but also in
tumors of UC-associated cancer.6 In
mouse models of intestinal colitis it was
shown that IL-21 exaggerates intestinal
acute colitis and that IL-21 is expressed in
tumor-infiltrating lymphocytes in a colitis-
associated cancer model.6
In our recent study our aim was to
investigate the function of IL-21 during
the development of colitis-associated
tumorigenesis and its importance in tumor
immunosurveillance.7 We analyzed the
course of chronic colitis in IL-21 deficient
mice. Likewise to the acute colitis, we
observed a dampened inflammation asso-
ciated with intact colon architecture and
decreased proliferation of intestinal cells in
IL-21-deficient mice compared with wild-
type (WT) mice due to diminished levels
of IFNc and IL-17. Opposing to previous
results in the acute colitis, we found
no alterations in Tregs levels in IL-21-
deficient mice during chronic colitis.8
Surprisingly, when we combined chronic
colitis with tumorigenesis, IL-21 deficient
mice showed a similar extent of inflam-
mation compared with wild-type mice but
less tumor burden. The tumors from
IL-21 deficient mice were also reduced in
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diameter. This effect was due to low
tumor cell proliferation and high tumor
cell apoptosis in IL-21-deficient mice.
The intestinal cytokine milieu of IL-21
deficient mice with colitis-associated colo-
rectal cancer showed a decrease in IL-17,
while IFNc is highly upregulated, which
in turn mediated the severe intestinal
inflammation. Simultaneously, the Th17
inducing cytokine IL-23 was elevated in
WT mice whereas the Th1 inducing
cytokine IL-12p70 was upregulated in
IL-21-deficient mice. Other protumoral
cytokines like IL-6 and IL-22 remain
unchanged in IL-21-deficient mice. This
cytokine switch from a Th17-dominated
cytokine milieu toward a Th1-dominated
one happens during the transition phase
from acute to chronic intestinal inflam-
mation and is based on epithelial-derived
factors that are stimulating antigen-
presenting cells to induce this specific
adaptive immune responses. In our
studies we could verify that the increased
IFNc levels are the reason for an
enhanced antitumor response mediated
by CD103+CD8+ cytotoxic cells specific
for tumor cells. These CD103+CD8+
T cells were elevated in IL-21-deficient
mice in the course of colitis-associated
tumorigenesis. Further these cells showed
an enhanced cytotoxic potential against
E-cadherinhigh-expressing tumor cells. In a
similar subsequent study Stolfi et al.
additionally showed reduced infiltration
of alternatively activated macrophages,
myeloid derived suppressor cells and
reduced phosphorylation of STAT3 and
diminished levels of Bcl-XL in IL-21
deficient mice.6
In conclusion, our results clearly eluci-
date that IL-21 has a prominent function
in tumor growth and immunosurveillance
of colitis-associated tumorigenesis. IL-21
controls the balance between Th17 and
Th1 cell subsets and therewith is necessary
for the homeostasis of a tumor-supportive
microenvironment characterized by exten-
sive inflitration of Th17 cells. In addition,
IL-21 controls the development of cyto-
toxic CD103+CD8+ T cells whose cyto-
toxic capacity is also diminished in the
presence of IL-21.
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Adenoma-linked barrier defects and microbial
productsdrive IL-23/IL-17-mediated tumourgrowth
Sergei I. Grivennikov1*, Kepeng Wang1,2*, Daniel Mucida3,4, C. Andrew Stewart5, Bernd Schnabl6, Dominik Jauch1,
Koji Taniguchi1,7, Guann-Yi Yu1, Christoph H. O¨sterreicher6,8, Kenneth E. Hung9, Christian Datz10, Ying Feng11, Eric R. Fearon11,
Mohamed Oukka12, Lino Tessarollo13, Vincenzo Coppola14, Felix Yarovinsky15, Hilde Cheroutre3, Lars Eckmann6,
Giorgio Trinchieri5 & Michael Karin1
Approximately 2% of colorectal cancer is linked to pre-existing
inflammation knownas colitis-associated cancer, butmost develops
in patients without underlying inflammatory bowel disease.
Colorectal cancer often follows a genetic pathway whereby loss of
the adenomatous polyposis coli (APC) tumour suppressor and
activation of b-catenin are followed by mutations in K-Ras,
PIK3CA and TP53, as the tumour emerges and progresses1,2.
Curiously, however, ‘inflammatory signature’ genes characteristic
of colitis-associated cancer are also upregulated in colorectal can-
cer3,4. Further, like most solid tumours, colorectal cancer exhibits
immune/inflammatory infiltrates5, referred to as ‘tumour-elicited
inflammation’6. Although infiltrating CD41 TH1 cells and CD8
1
cytotoxic T cells constitute a positive prognostic sign in colorectal
cancer7,8, myeloid cells and T-helper interleukin (IL)-17-producing
(TH17) cells promote tumorigenesis5,6, and a ‘TH17 expression
signature’ in stage I/II colorectal cancer is associated with a drastic
decrease in disease-free survival9. Despite its pathogenic importance,
the mechanisms responsible for the appearance of tumour-elicited
inflammation are poorly understood. Many epithelial cancers
develop proximally to microbial communities, which are physically
separated from immune cells by an epithelial barrier10. We investi-
gatedmechanisms responsible for tumour-elicited inflammation in
amousemodel of colorectal tumorigenesis, which, like human colo-
rectal cancer, exhibits upregulation of IL-23 and IL-17. Here we
show that IL-23 signalling promotes tumour growth and progres-
sion, and development of a tumoural IL-17 response. IL-23 is
mainly produced by tumour-associated myeloid cells that are likely
to be activated bymicrobial products, which penetrate the tumours
but not adjacent tissue. Both early and late colorectal neoplasms
exhibit defective expression of several barrier proteins.We propose
that barrier deterioration induced by colorectal-cancer-initiating
genetic lesions results in adenoma invasion by microbial products
that trigger tumour-elicited inflammation, which in turn drives
tumour growth.
Specimens of human colorectal cancer (CRC) show increased
expression of IL-23p19 and IL-17A messenger RNA (mRNAs)
(Fig. 1a). IL-23p19 is the specific subunit of IL-23, a positive regulator
of TH17 and other IL-17-producing cells11, previously found to pro-
mote skin carcinogenesis12. To address the role of these cytokines in
CRC-related tumour-elicited inflammation and tumour growth, we
used ApcF/wt mice that harboured a Cdx2-Cre transgene (CPC-APC
mice) in which colorectal tumorigenesis was driven by Apc allelic
loss13. UnlikeApcMinmice, CPC-APCmice develop tumours primarily
in the distal colon, providing a relevantmodel of humanCRC13.Mouse
colon tumours also exhibitedmarked upregulation of IL-23 and IL-17A
mRNA and IL-23 protein relative to matched non-tumour colon
(Fig. 1b, c). IL-23 induction was specific, as tumoural expression of
other IL-12/23 family members was not substantially elevated and
IL-23 itself was already seen in early tumours (Supplementary Fig.
1a, b). IL-23 expression did not further increase in more advanced
mouse CRC caused by Apc loss and forced K-Ras or B-Raf activation
(Supplementary Fig. 1c). Analysis of Il232/2 mice harbouring green
fluorescent protein (GFP) gene in the Il23p19 locus, staining with IL-
23p19 antibody and flow cytometry showed that IL-23p19 is parti-
cularly expressed in tumour-infiltrating cells such as CD11b1 and
F4/801 myeloid cells (Supplementary Fig. 1d–f). Both IL-23 subunits,
p19 and p40, need to be simultaneously expressed to generate a func-
tional cytokine.Analysis by quantitative PCRwith reverse transcription
(RT–qPCR) and fluorescence-activated cell sorting (FACS) of tumoural
cell populations showed that CD11b1 cells expressed substantial
amounts of both p19 and p40 (Fig. 1d). TH17- and other IL-17-pro-
ducing cells were detected in mesenteric lymph nodes and tumours of
CPC-APC mice and demonstrated dependence on IL-23 signalling
(Fig. 1e). Thus, expression of IL-23 and its downstream target IL-17A
is increased during spontaneous colorectal tumorigenesis.
Colorectal tumour multiplicity and growth were diminished upon
ablation of IL-23 or IL-23R in CPC-APC mice (Fig. 1f, g and Sup-
plementary Fig. 2a). Although intra-tumoural apoptosis was unaffected,
cancer cell proliferation was reduced in Il232/2/CPC-APC mice
(Supplementary Fig. 2b, c). Epithelial STAT3 phosphorylation was
decreased without IL-23, but genetically driven nuclear b-catenin
accumulation was unaffected (Fig. 1g and Supplementary Fig. 2d).
IL-23 signalling was important for intra-tumoural production of
downstream cytokines, which are either direct (IL-6, IL-22) or indirect
(IL-17A) STAT3 activators (Fig. 1h). Pro-tumorigenic IL-23 signalling
was particularly confined to the haematopoietic compartment, as
CPC-APC chimaeras harbouring Il23–/– or Il23rgfp/gfp bone marrow
also exhibited reduced tumour load (Supplementary Fig. 3a–d) and
diminished expression of IL-23-dependent cytokines (Supplementary
Fig. 3e). To examine the role of IL-17 signalling in CRC tumorigenesis,
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we crossedCPC-APCmicewith Il17ra2/2mice, which donot respond
to either IL-17A or IL-17F. Both tumourmultiplicity and growth were
reduced in the absence of IL-17RA (Supplementary Fig. 4a–c).
We examined the cause of IL-23 upregulation in CRC. The com-
mensal microflora regulates basal colonic IL-23 expression in naive
mice14. Microbial products are sensed by Toll-like receptors (TLRs),
which rely on the adaptors MyD88 and TRIF15. Similar to its effect on
small intestinal polyps in ApcMin mice16, whole body MyD88 ablation
reduced tumour multiplicity and growth in CPC-APC mice (data
not shown). We transplantedMyd882/2, Tlr2,4,92/2 triple knockout
or control bone marrow into lethally irradiated CPC-APC mice.
Expression of IL-23p19 mRNA by sorted tumoural myeloid cells
was decreased upon TLR/MyD88 inactivation in the haematopoietic
compartment (Fig. 2a). Intratumoural expression of IL-6 and IL-17A
was also dependent onMyD88 in bone-marrow-derived cells (Fig. 2b).
Transplantation with Myd88–/– or Tlr2,4,92/2 bone marrow reduced
colorectal tumour growth (Fig. 2c and Supplementary Fig. 5). By con-
trast, deletion of IL-18R in bonemarrowhadno effect on tumorigenesis
or IL-23 production by TAM (Supplementary Fig. 6a, b). Short-term
depletion of intestinalmicroflorawith a combination of broad-spectrum
antibiotics, which reducedmicrobial counts by over 99.9%, also inhib-
ited IL-23 expression by TAM, resulting in reduced tumoural IL-
17A and decreased STAT3 activation in cancer cells (Fig. 2d–f).
Prolonged depletion of commensal microflora by antibiotic treatment
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Figure 1 | IL-23 controls CRC inflammation and tumorigenesis. a, b, RT–
qPCR for IL-23p19 and IL-17A mRNAs from colorectal tumours (T) and
matching normal (N) colons of (a) human CRC patients (n5 7, P5 0.037 for
IL-23p19) or (b) CPC-APC mice (n5 8, P5 53 1025, 3.63 1024,
respectively). c, IL-23 protein was measured by ELISA in supernatants of
cultured tumours and normal tissues of CPC-APC mice (n5 5, P5 0.04).
d, RT–qPCR analysis of sorted haematopoietic myeloid cells
(CD451TCRb2CD11b1) from tumours of CPC-APC mice (n5 4; pooled);
populations: CD11b15Gr12F4/80low; Gr115Gr11F4/802;
Gr1high5Gr1highF4/802; F4/8015Gr12/dimF4/801 and T cells
(CD451TCRb1). e, Intracellular cytokine staining of phorbolmyristate acetate
and ionomycin re-stimulated cells (Live/Dead2CD451 gate). f, Five-month-
old Il232/2 and control CPC-APCmice were killed and tumour numbers, size
and load were determined (n5 7, P5 0.04, 0.03, 0.01, respectively). g, Tumour
sections were stained with haematoxylin and eosin or phospho-STAT3 and
b-catenin antibodies. h, Cytokine mRNA analysis by RT–qPCR in mesenteric
lymph nodes (MLN), normal (N) and tumour (T) tissue of 5-month-old
Il232/2 and control CPC-APC mice (n5 6, P5 0.044, 0.007, 0.045,
respectively). Data represent averages6 s.e.m. *P, 0.05. Scale bars, 100mm.
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for 3.5months starting at weaning reduced tumour size and load in
control CPC-APC mice but not in Il23r2/2/CPC-APC counterparts
(Fig. 2g), emphasizing the importance ofmicrobial product-driven IL-
23 signalling.
By injecting fluorescein isothyocyanate (FITC)-labelleddextran into
clamped colonic loops, we found that tumour development in CPC-
APCmice was associated with translocation of FITC-dextran into the
circulation (Fig. 3a). This suggested that CRC development may result
in increased penetration of microbial products or microbes into
tumours. Indeed, Alexa488-labelled lipopolysaccharide (LPS) injected
into colonic loops of CPC-APCmice translocated into tumours where
it particularly co-localized with F4/801 TAMs, but did not penetrate
adjacent normal tissue (Fig. 3b). Tumour development also coincided
with elevated endotoxin in portal blood (Fig. 3c). Occasional bacteria
were detected by in situ hybridization with a eubacterial 16S ribosomal
RNA (rRNA) probe within colorectal tumours (Fig. 3d) and proxi-
mal to tumour epithelial cells in mouse early lesions that resembled
aberrant crypt foci and early human adenomas (Fig. 3e, f).
Mucus from goblet cells prevents bacterial penetration through the
colonic epithelial barrier. Correspondingly, Muc22/2 mice develop
spontaneous colitis followed by colitis-associated cancer17,18. Periodic
acid-Schiff staining indicated absence of mucus-producing cells and
mucins in tumours but not in adjacent normal tissue (Fig. 4a). Staining
with wheat germ agglutinin (WGA) for glycosylated mucus proteins
and mucin 2 (Muc2)-specific antibody demonstrated markedly
reduced Muc2 production and coating of tumour tissue (Fig. 4a).
Muc2 was barely detected in human CRC, but was prominent in
adjacent normal tissues (Fig. 4b). Muc2 mRNA was downregulated
in human and mouse colorectal tumours relative to healthy tissues
(Supplementary Fig. 7a, b). Epithelial barriers also depend on tight
and adherent junctions10. Human CRC demonstrated notable loss of
polarized expression of junctional proteins JAM-A and JAM-B
(Fig. 4c). JAM-A/B mRNAs were also reduced in human CRC and
JAM-CmRNAwas downregulated inmouse tumours (Supplementary
Fig. 7a, b) Although claudin 4 mRNA was not downregulated in
human or mouse tumours (Supplementary Fig. 7a, b), the protein
was no longer distinctly localized to tight junctions in human ormouse
tumours, similar to claudins 3, 5 and 7 (Supplementary Fig. 8a, b).
Early human adenomas also showed defective mucin expression and
organization of tight junctions (Fig. 4d), coincidingwith elevated IL-23
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Figure 2 | TLR-MyD88 signalling and commensal microflora promote
cytokine expression and tumorigenesis. a–c, CPC-APC mice were
transplanted with Myd882/2, Tlr2,4,92/2 or control bone marrow (BM) and
analysed 4months later by RT–qPCR for cytokine mRNAs in sorted tumour
myeloid cells (Live/Dead2 TCRb2 CD11b1), representative of two independent
experiments, each including four pooled mice (a) or in tumours and normal
tissues (n5 5, P5 0.004, 0.032) (b). c, Tumour number, size and load in mice
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normal and tumour tissues from the control and Abx-treated CPC-APC mice
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0.043). Data represent averages6 s.e.m. *P, 0.05. Scale bars, 50mm.
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and IL-17A in adenoma tissue (Supplementary Fig. 9a). Early CRC
lesions, such as aberrant crypt foci, are marked by enhanced express-
ion and nuclear translocation of b-catenin, and such areas were devoid
of WGA and JAM-A staining (Fig. 4e). To demonstrate further that
barrier loss is an early and direct consequence of tumour emergence,
we studied rapid colonic transformation in Cdx2ERT-Cre 3 ApcF/F
mice using tamoxifen to induce bi-allelic APC inactivation. APC loss
resulted in patches of proliferating transformed cells with enlarged
nuclei, which coincided with loss of mucin and induction of IL-23
(Fig. 4f and Supplementary Fig. 9b).
Nearly all solidmalignancies contain inflammatory infiltrates, influ-
encing tumour promotion, progression and metastasis5,6. The contri-
bution of inflammation to CRC pathogenesis is emphasized by the
protective effect of non-steroidal anti-inflammatory drugs, such as
aspirin19, but sources of tumour-elicited inflammation in CRC
were heretofore unknown. We now suggest that early CRC-inducing
genetic events may cause local loss of barrier function and entry of
microbial products into the tumourmicroenvironment. This results in
activation of IL-23-producingmyeloid cells, which regulate expression
of downstream tumour-promoting cytokines, including IL-17 and
IL-6. A similar mechanism may apply to other cancers that develop
in epithelia that are exposed to commensal and pathogenic bacteria.
Deregulation of tight junctions and cell–cell contacts was described in
advanced human adenocarcinomas, but suggested to cause detachment
of carcinoma cells from their neighbours, increased motility and meta-
stasis20. The importance of the mucus layer is emphasized by whole
body Muc2 deficiency, which causes colonic inflammation17,18. Pro-
longed treatment with dextran sulphate sodium, which promotes
development of colitis-associated cancer in wild type (WT) or ApcMin
mice, also causes erosionof the intestinal epithelial barrier andmicrobial-
dependent inflammation21,22, and so do the barrier-disrupting patho-
gensCitrobacter rodentium23 and enterotoxicBacteroides fragilis24. The
commensal microflora was suggested to promote adenoma develop-
ment, as germ-free ApcMin mice exhibit a twofold reduction in
small intestinal adenomas25 and Tbx212/2;Rag22/2 ulcerative colitis
(TRUC), and Il102/2 mice fail to develop colitis-associated cancer
when rendered germ-free26,27. Our work demonstrates that defective
expression of barrier proteins is an early event in CRC tumorigenesis,
coupled to upregulation of IL-23 and its downstream cytokines. We
also found that IL-23 does not act directly on adenoma cells and that its
receptor is expressed and signals within the haematopoietic compart-
ment. Probably, IL-23 acts through IL-17 family members, as ablation
of IL-17R attenuated colorectal tumorigenesis. IL-23 is instrumental
for stabilizing the ‘TH17 signature’, which includes IL-17A, RORct and
IL-23R, and was linked to extremely poor prognosis in human stage
I/II CRC, which otherwise show 75–90% survival9. IL-23 itself is not
a part of the ‘TH17 signature’, arguably because its expression is
already elevated in early colorectal tumours. The ‘IL-23/TH17’ and
‘TH1-cytotoxic’ signatures are not mutually exclusive in human
CRC9. Although in genetically uniform mice in barrier facilities
IL-23 invariably leads to IL-17 induction, the genetic heterogeneity
of human populations and their exposure to a broader spectrum of
microbes may explain why certain individuals mount a stronger TH17
response than others. TH17 development is promoted by several cyto-
kines, including IL-21, IL-6 and IL-1, all of which can be induced by
microbial components28. It remains to be investigated which of these
cytokines contributes to the tumoural TH17 response and how it is
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affected by distinct microflora components. Segmented filamentious
bacteria persisting in proximity to epithelial cells initiate TH17 res-
ponses in the small intestine29. In tumours lacking protective barrier,
other microbial species and products may invade the tumour and
influence the ‘IL-23/TH17’ signature.
Loss of APC and activation of b-catenin induces a proliferative state
and blocks the differentiation of certain IEC lineages, including
mucin-producing goblet cells30. Epithelial barrier loss may therefore
be a consequence of b-catenin activation and/or of APC loss, which
apart from b-catenin can also control cytoskeleton dynamics. Hence,
early barrier loss and activation of IL-23/IL-17-driven tumour-elicited
inflammation act additively and sequentially to genetically controlled
events that govern CRC development and progression (Supplemen-
tary Fig. 10). We propose that screening of early tumours for IL-17
expression and adjuvant treatment of patients showing a ‘TH17
signature’ with IL-23 or IL-17 antagonists should reduce mortality
due to CRC.
METHODS SUMMARY
Mice were backcrossed to the C57BL/6 background for at least seven (CPC-APC)
or ten (others) generations and maintained and studied in filter-topped cages on
autoclaved food and water in a barrier facility at the University of California, San
Diego, according to institutional and National Institutes of Health (NIH) guide-
lines. Male and female mice were used in this study, including littermate and cage
mate controls. Il23rF/F mice were generated by C.A.S., L.T., V.C. and G.T.
(Supplementary Fig. 11). Cdx2ERT-Cre mice were generated and maintained by
Y.F. and E.R.F. and will be reported elsewhere. Mice were allowed to develop
spontaneous CRC for 4–5 months. At the end of each study, mice were killed
and colonic tumours and non-tumour tissue, along with mesenteric lymph nodes,
were analysed using flow cytometry, enzyme-linked immunosorbent assay
(ELISA), RT–qPCR, immunohistochemistry and fluorescent microscopy.
Lethally irradiated (23 600 rad) littermate CPC-APC recipient mice were intra-
venously injected with 107 nucleated bone marrow cells from various donors to
generate radiation chimaeras. Endotoxin was measured in portal vein blood/
plasma by a Limulus assay. For intestinal permeability analysis, tumour-bearing
and control mice were surgically clipped and FITC-dextran or Alexa488-LPSwere
injected into the colonic lumen, followed by fluorescent detection of FITC in
serum or Alexa488-LPS in frozen colon sections.
Full Methods and any associated references are available in the online version of
the paper.
Received 8 February; accepted 31 July 2012.
Published online 3October; correctedonline 7November 2012 (see full-text HTML
version for details).
1. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control.Nature
Med. 10, 789–799 (2004).
2. Fearon, E. R. & Vogelstein, B. A geneticmodel for colorectal tumorigenesis.Cell61,
759–767 (1990).
3. Wood, L. D. et al. Thegenomic landscapes of humanbreast and colorectal cancers.
Science 318, 1108–1113 (2007).
4. Reichling, T. et al. Transcriptional profiles of intestinal tumors inApc(Min)mice are
unique from those of embryonic intestine and identify novel gene targets
dysregulated in human colorectal tumors. Cancer Res. 65, 166–176 (2005).
5. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation.
Nature 454, 436–444 (2008).
6. Grivennikov, S. I., Greten, F. R. &Karin,M. Immunity, inflammation, andcancer.Cell
140, 883–899 (2010).
7. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating
immunity’s roles in cancer suppression andpromotion. Science 331,1565–1570
(2011).
8. Galon, J. et al. Type, density, and location of immune cells within human colorectal
tumors predict clinical outcome. Science 313, 1960–1964 (2006).
9. Tosolini, M. et al. Clinical impact of different classes of infiltrating T cytotoxic and
helper cells (Th1, th2, treg, th17) inpatients with colorectal cancer.Cancer Res.71,
1263–1271 (2011).
10. Brenchley, J. M. & Douek, D. C. Microbial translocation across the GI tract. Annu.
Rev. Immunol. 30, 149–173 (2012).
11. McKenzie, B.S., Kastelein, R. A. &Cua,D. J.Understanding the IL-23-IL-17 immune
pathway. Trends Immunol. 27, 17–23 (2006).
12. Langowski, J. L. et al. IL-23 promotes tumour incidence and growth. Nature 442,
461–465 (2006).
13. Hinoi, T. et al.Mousemodel of colonic adenoma-carcinoma progression based on
somatic Apc inactivation. Cancer Res. 67, 9721–9730 (2007).
14. Sawa, S. et al. RORct1 innate lymphoid cells regulate intestinal homeostasis by
integrating negative signals from the symbiotic microbiota. Nature Immunol. 12,
320–326 (2011).
15. Medzhitov, R. Recognition of microorganisms and activation of the immune
response. Nature 449, 819–826 (2007).
16. Rakoff-Nahoum, S. & Medzhitov, R. Regulation of spontaneous intestinal
tumorigenesis through the adaptor protein MyD88. Science 317, 124–127
(2007).
17. Van der Sluis, M. et al.Muc2-deficient mice spontaneously develop colitis,
indicating that MUC2 is critical for colonic protection. Gastroenterology 131,
117–129 (2006).
18. Velcich, A. et al.Colorectal cancer inmice genetically deficient in themucin Muc2.
Science 295, 1726–1729 (2002).
19. Rothwell, P.M. et al. Effect of daily aspirin on long-term risk of death due to cancer:
analysis of individual patient data from randomised trials. Lancet 377, 31–41
(2011).
20. Wang,X., Tully,O., Ngo,B., Zitin,M.&Mullin, J.M.Epithelial tight junctional changes
in colorectal cancer tissues. Sci. World J. 11, 826–841 (2011).
21. Tanaka, T. et al. Dextran sodium sulfate strongly promotes colorectal
carcinogenesis in Apc(Min/1) mice: inflammatory stimuli by dextran sodium
sulfate results in development of multiple colonic neoplasms. Int. J. Cancer 118,
25–34 (2006).
22. Meira, L. B. et al. DNA damage induced by chronic inflammation contributes to
colon carcinogenesis in mice. J. Clin. Invest. 118, 2516–2525 (2008).
23. Newman, J. V., Kosaka, T., Sheppard, B. J., Fox, J. G. & Schauer, D. B. Bacterial
infection promotes colon tumorigenesis in Apc(Min/1) mice. J. Infect. Dis. 184,
227–230 (2001).
24. Wu, S. et al. A human colonic commensal promotes colon tumorigenesis via
activation of T helper type 17 T cell responses. Nature Med. 15, 1016–1022
(2009).
25. Dove,W. F. et al. Intestinal neoplasia in theApcMinmouse: independence from the
microbial and natural killer (beige locus) status. Cancer Res. 57, 812–814 (1997).
26. Yang, L. & Pei, Z. Bacteria, inflammation, and colon cancer.World J. Gastroenterol.
12, 6741–6746 (2006).
27. Garrett,W.S.et al.Colitis-associatedcolorectal cancerdrivenbyT-bet deficiency in
dendritic cells. Cancer Cell 16, 208–219 (2009).
28. Zhou, L. et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential
engagement of the IL-21 and IL-23 pathways. Nature Immunol. 8, 967–974
(2007).
29. Ivanov, I. I. et al. Specific microbiota direct the differentiation of IL-17-producing
T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337–349
(2008).
30. Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature
457, 608–611 (2009).
Supplementary Information is available in the online version of the paper.
AcknowledgementsWe thank eBioscience, GeneTex, Santa Cruz, BioLegend and Cell
Signaling for antibodies; Genentech and Amgen for Il232/2 and Il17ra2/2mice,
respectively, and S. Reid and E. Southon for the help in generating Il23rF/F mice. This
work was supported by Crohn’s and Colitis Foundation of America (Career
Development Award number 2693), NIH/National Institute of Diabetes and Digestive
and Kidney Diseases (K99-DK088589) and a University of California, San Diego,
Digestive Disease Research Development Center Pilot Grant (DK080506) to S.I.G.;
Croucher Foundation and China Postdoctoral Science Foundation (20110490919) to
K.W.; Strategic Young Researcher Overseas Visits Program for Accelerating Brain
Circulation to K.T.; SPAR Austria to C.D.; NIH (R01CA082223) to E.R.F.; and NIH
(AI043477; DK035108) and American Association for Cancer Research
(07-60-21-KARI) grants to M.K., who is an American Cancer Society Research
Professor. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the NIH.
Author Contributions S.G. and M.K. conceived the project. S.I.G., K.W., D.M., B.S., D.J.,
K.T., G.Y.Y., C.O., Y.F. and K.E.H. performed the experiments. S.I.G., K.W., D.M., D.J., H.C.,
L.E. and M.K. analysed data. C.A.S., V.C., L.T. and G.T. generated Il23rF/F mice. M.O. and
F.Y. provided Il23rgfp/gfp and Tlr2,4,92/2 bonemarrow, respectively, and Y.F. and E.R.F.
provided CPC-APCmice and tissues fromCdx2ERT-Cre-APCmice. C.A.S., E.R.F., H.C. and
G.T. provided conceptual advice. C.D. collected and provided human specimens. S.I.G.,
K.W. and M.K. wrote the manuscript, with all authors contributing to the writing and
providing advice.
Author Information Reprints and permissions information is available at
www.nature.com/reprints. The authors declare no competing financial interests.
Readers are welcome to comment on the online version of the paper. Correspondence
and requests for materials should be addressed to M.K. (karinoffice@ucsd.edu).
RESEARCH LETTER
2 5 8 | N A T U R E | V O L 4 9 1 | 8 N O V E M B E R 2 0 1 2
Macmillan Publishers Limited. All rights reserved©2012
44
METHODS
Human samples. Paraffin-embedded human ulcerative colitis and CRC speci-
mens were provided by Oberndorf Hospital, Paracelsus Medical University
Salzburg, Austria. Patients with ulcerative colitis or sporadic CRC underwent
colonoscopy as a part of the diagnostic workup at the Department of Internal
Medicine, Oberndorf Hospital (Salzburg, Austria). Diagnosis of ulcerative colitis
was based on appropriate clinical, endoscopic, histopathological and radiological
findings that satisfied the internationally accepted Lennard-Jones criteria31.
Additionally, colonoscopic findings were classified as tubular adenoma, size less
than 6mm (early lesion), advanced adenoma (that is, villous or tubulovillous
features), size at least 1 cm or high-grade dysplasia or carcinoma after a combined
analysis of macroscopic and histological results32,33. Biopsies from colonic tissue
with macroscopically normal appearance were taken in patients who underwent
colonoscopy for CRC screening. For histological examination, specimens were
fixed in 4%buffered formalin and embedded into paraffin.When available, a small
tissue portion of the biopsy specimen was separated and preserved for RNA and
protein extraction in RNAlater (Ambion’s RNAlater solution, Applera, Brunn am
Gebirge, Austria). Biopsies from colonic tissue with macroscopically normal
appearancewere taken in patients who underwent colonoscopy for CRC screening.
Written informed consent was obtained from all study participants to use one
biopsy specimen for scientific purposes. The study was approved by the local ethics
committee (Ethikommission des Landes Salzburg, approval number 415-E/1262/
2-2010). Frozen human CRC and normal colon tissues were obtained from
Cooperative Human Tissue Network of Vanderbilt University Medical Center.
Generation of Il23rF/F and Il23r2/2mice. The targeted region includes exons 2
(3,708–3,810) and 3 (8,085–8,381) of Il23r that encode a portion of the signal
peptide and the amino (N)-terminal Ig-like domain (Supplementary Fig. 11a). The
targeting vector was generated by recombineering using l phage Red as described
by Liu et al.34. Homology arms for the retrieval vector were amplified by PCR on
C57BL/6 genomic DNA. Homology arms were cloned into pLMJ235 (pBSKS1
containing a 2.8kb SalI TK fragment of pGKTK) by triple ligation to form
the retrieval plasmid. Retrieval of the targeting region (covering 753-12,812; num-
bering relative to indicated BamHI site) was performed according to Liu et al.34
using C57BL/6 bacterial artificial chromosome RP23-283M8 (BACPAC
Resources) as template in DY380 cells. Recombineering was performed to insert
cassettes containing LoxP-flanked Neo cassettes from pGKEM7Neo-pA into the
targeting vector. First, LoxP-Neo-LoxP was inserted at position 3,524, followed by
induced expression of Cre in EL350 cells to excise the Neo selection cassette but
leaving the upstream LoxP site. A second cassette (LoxP-Frt-Intron-Eng2SA-Neo-
LoxP-Frt) was inserted into position 8,503. After NotI-linearization, the targeting
construct was electroporated into Bruce 4 C57BL/6 ES cells, and G418-selected
clones were screened for integration by Southern analysis using sequences outside
the targeting vector (Supplementary Fig. 11b). Selected clones were injected into
C57BL/6-albino blastocysts and transferred to pseudopregnant females. Chimeric
offspring were bred with C57BL/6-Albino partners to generate F1 mice that were
screened for integration by Southern blotting (Supplementary Fig. 11c). Resulting
micewith the Il23rSA-F-neo allelewere crossedwithC57BL/6-FLPemice to facilitate
recombination between Frt sequences and generate the Il23rF allele. The null allele
(Il123r2/2) was generated by crossing Il23rF/FmicewithCPC-Cre transgenicmice.
The F2 generation exhibits germline deletion of floxed alleles owing to early CPC-
Cre expression in caudal regions of the body and gonads13. Complete ablation of
IL-23R was confirmed by RT–qPCR of spleen and tumour-derived cells.
Animal models.C57BL/6 control mice obtained fromCharles River Laboratories
were bred locally at University of California, San Diego. Il232/2 and Il17ra2/2
mice were from Genentech35 and Amgen36, respectively. Bone marrow from
Il23rgfp/gfp and Tlr2,4,92/2mice was provided by M. Oukka37 and F. Yarovinsky38,
respectively. ApcF/F and Cdx2-Cre (CPC-Cre) mice13 were provided by E. Fearon,
who also generated the Cdx2-CreERT mice, which will be described elsewhere.
Myd882/2mice39 were obtained from the Jackson Laboratory, and Il18r2/2mice40
were from H. Hoffman. All mice were maintained in filter-topped cages on
autoclaved food and water at University of California, San Diego, according to
NIH guidelines, and all experiments were performed in accordance with
University of California, San Diego, and NIH guidelines and regulations. Most
experiments used littermate controls housed in the same cage; in addition, dirty
beddings were switched between cages of the same experiment to make sure that
the microflora was balanced.
For spontaneous CRC tumorigenesis, male and female CPC-APC mice were
allowed to develop colorectal tumours spontaneously for 4–5 months and then
killed. Macroscopic tumours were counted and their diameter measured with a
calliper. Average tumour size per individual mouse was determined by averaging
diameters of all tumours present. Tumour load was determined as the sum of the
diameters of all tumours presented in a given mouse, as previously described41.
Typically, one-half of the distal colon was taken as a tissue sample, tumours and
normal tissue dissected and snap-frozen in liquid nitrogen or used for ex vivo
cultures or fluorescence-activated cell sorting. The other half was fixed in 10%
neutral buffered formalin for 24 h and transferred to 70% ethanol for subsequent
paraffin embedding, or alternatively frozen in optimal cutting temperature (OCT)
compound for further sectioning and histological analysis.
To induce colorectal tumours with inactivated Apc and activated K-Ras or
B-Raf, open laparotomies were performed in mice bearing floxed Apc (ApcF/F)
in combination with either latent KrasG12D (Apc-Kras) or BrafV600E (Apc-Braf)
alleles under isofluorane anaesthesia. Adosage of adenovirus-Crewas administered
to the distal colon, which resulted in solitary colonic tumours, as described42,43.
Subsequent tumour formation was monitored by serial optical colonoscopy.
Tumours were collected after more than 75% occlusion of the colonic lumen was
observed and banked in RNA later for subsequent analysis.
Colonic loops and injections of FITC-dextran and Alexa488-LPS.After anaes-
thesia, a midline laparotomy incision was made. A 2–3 cm long segment of the
colon with or without tumours inside was created with two vascular haemoclips
without disrupting the mesenteric vascular arcades. The length of intestine
between the two clips was injected with 50ml of 100mgml21 FITC-dextran solu-
tion or 50ml of Alexa488-LPS at 70mg per mouse. At the indicated time points,
mice were killed and fluorescence was measured in the plasma with a fluorimeter,
or colon fragments were embedded into OCT compound, and frozen sections pre-
pared and analysed for Alexa488-LPS tissue distribution by fluorescent microscopy.
Antibiotic treatment.Mice were given the following antibiotics in their drinking
water: 100mgml21 neomycin, 50mgml21 vancomycin, 50mgml21 imipenem,
100mgml21 metronidazole, 50mgml21 streptomycin and 100Uml21 penicillin.
Fresh antibioticswere supplied everyweek. For long-term antibiotic treatment after
2months of initial treatment, drinking water was further supplemented with strep-
tomycin (1mgml21), gentamycin (170mgml21), ciprofloxacin (125mgml21) and
bacitracin 1mgml21 aspreviously described44. Controlmicewere placedonbottled
water. Faeces were collected and cultured on 5% sheep blood agar plates (Fisher
Scientific) under aerobic or anaerobic conditions at 37 uC todetermine the extent of
colon sterilization, which exceeded 99.9%. Alternatively, DNA was isolated from
stools of mice using QIAamp DNA Stool mini kit (Qiagen) and content of 16S
bacterial rRNA was analysed by RT–qPCR. Mice were kept on antibiotics for the
indicated time and killed for tumour and tissue analysis.
Portal blood vein drainage and endotoxin measurement. Mice were anaes-
thetized with isofluorane and their portal vein exposed to insert a 28-gauge needle
and draw 100–200ml of blood, which was collected into EDTA coated tubes (BD
Biosciences). Plasma was isolated by centrifugation and endotoxin amounts were
determined bymicroplate LimulusAmebocyte Lysate (LAL) colorimetric bioassay
(Lonza) according to the manufacturer’s recommendations.
Bone marrow transplantation. Six- to eight-week-old littermate recipient mice
were irradiated twice during one day to achieve a lethal dose (2 3 600 rad) and
intravenously injected with single-cell suspension containing 107 donor bone
marrow cells. Every cage of recipient mice contained mice receiving both gene-
deficient and wild-type bonemarrow to comparemice living in the same cage. For
2weeks after irradiation, mice were placed on sulphamethoxazole and trime-
thoprime antibiotics in drinking water followed by transfer to the cages from
the same room/rack with dirty bedding to restore microflora. Mice were killed
and analysed for tumour development 4–5 months after transplantation.
Antibodies and stains. Fluorescent-labelled antibodies for flow cytometry were
from eBioscience. Immunoblot analysis and immunohistochemistry were per-
formed with antibodies to Ki-67, claudin7, claudin 5, claudin 4, claudin 3, JAM-B,
mucin2,GFP, IL-23p19 (Genetex), JAM-A(SantaCruz), active caspase 3, phospho-
STAT3 (Cell Signaling), F4/80 and E-cadherin (BD Biosciences). Secondary anti-
bodies (host: donkey) for fluorescent microscopy labelled with Alexa 488 or 594
were from Invitrogen. For TdT-mediated dUTP nick end labelling (TUNEL) assay
the In situ Cell Death Kit (Roche) was used according to the manufacturer’s
recommendations. Alexa488-LPS and Oregon488-WGA were from Invitrogen.
Immunohistology. Paraffin-embedded slides were de-paraffinized. Antigen
unmasking was performed by incubation in 94 uC water bath in 10mM sodium
citrate buffer with 0.1% Tween 20 for 1 h. Slides were incubated with primary
antibodies in PBS containing 1% BSA and 10% normal goat or donkey serum,
depending on the host of secondary antibodies used. Biotinylated secondary
anti-rat or anti-rabbit antibodies (Pharmingen)were added and incubated at room
temperature for 1 h. Streptavidin-HRP (Pharmingen) was added and after 40min
the sections were developed with DAB substrate and counterstained with haema-
toxylin. Alternatively, paraffin-embedded or acetone fixed frozen slides were
stained with antibodies followed by secondary donkey antibodies labelled with
Alexa488 or Alexa594, counterstained with DAPI and analysed by immunofluor-
escence. Images were acquired on an upright light/fluorescent Imager A2 micro-
cope (Zeiss) equipped with an AxioCam camera or on a confocal microscope
(Leica SPE).
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Bacteria fluorescent in situ hybridization. Paraffin embedded slides were de-
paraffinized andhybridized to universal eubacterial or control probes labelledwith
Alexa594. Hybridization was performed in 48 uC oven for 2 h followed bywashing
and counter-stained by DAPI. The sequences of the probes are listed below:
Eubacteria: GCTGCCTCCCGTAGGAGT; control: CGACGGAGGGCATCCTCA.
Flow cytometry and cell sorting. Isolated cellswere stainedwith labelled antibodies
in PBS with 2% FCS and analysed on a BD LSRII or on an Accuri C6 flow
cytometer. Dead cells were excluded on the basis of stainingwith Live/Dead fixable
Aqua dye (Invitrogen). For intracellular cytokine staining cell were restimulated in
the presence of Brefeldin A as indicated, fixed and permeabilized with Cytofix/
Cytoperm reagent (BD Biosciences) according to the manufacturer’s recommen-
dations and stained with labelled antibody for the cytokine of interest. For cell
sorting, a BD FACSAria II cell sorter was used. Data were analysed using FlowJo
software (Treestar).
ELISA. Pieces (20–40mg) of normal or tumour tissue were cultured in 0.5ml
RPMI medium supplemented with antibiotics and 2% FCS at 37 uC for 24 h.
Supernatants were collected, centrifuged and concentration of IL-23 protein was
determined using ELISA Quantikine kit (R&D Systems) according to the manu-
facturer’s recommendations.
RT–qPCR analysis. Total RNA was extracted using RNeasy Plus kit to eliminate
genomic DNA contamination (Qiagen). RNA was reverse transcribed using a
IScript kit (Biorad). RT–qPCR was performed using EvaGreen PCR mix
(Biorad) on a Biorad CFX96 machine. Expression data were normalized to L32
mRNAexpression. The data are presented in arbitrary units andwere calculated as
2(Ct(rpl32–gene of interest)). Primer sequences are listed in Supplementary Table 1
and generally were obtained from the NIH qPrimerDepot for mouse (http://
mouseprimerdepot.nci.nih.gov) and human (http://primerdepot.nci.nih.gov).
Whenever possible, primers were intron-spanning, such that amplification was
only feasible on complementary DNA.
Statistical analysis.Data are presented as averages6 s.e.m. and were analysed by
built-in t-test using Microsoft Excel software. P values less than 0.05 were con-
sidered significant.
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Supplementary Table 1: List of primers used for Q-RT-PCR. 
Human Q-RT-PCR 
Claudin 4 5’-TAACTGCTCAACCTGTCCCC-3’ 5’-ATAAAGCCAGTCCTGATGCG-3’ 
Claudin 5 5’-GCAGCCAATCACAGAGCC-3’ 5’-AGTGGTGTCACCTGAACTGG-3’
Claudin 7 5’-GCAAAATGTACGACTCGGTG-3’ 5’-CACAAACATGGCCAGGAAG-3’ 
IL-17A 5’-ACCAATCCCAAAAGGTCCTC-3’ 5’-CACTTTGCCTCCCAGATCAC-3’ 
IL-23 p19  5’-AGAAGCTCTGCACACTGGC-3’ 5’-CCACACTGGATATGGGGAAC-3’ 
JAM-A 5’-CCTCTTCATATTGGCGATCC-3’ 5’-CCAGTTGGCAAGAAGGTCAC-3’ 
MUC2 5’-GACACCATCTACCTCACCCG-3’ 5’-TGTAGGCATCGCTCTTCTCA-3’ 
Mouse Q-RT-PCR 
Claudin 4 5’-GGCGTAATGGCAAGAGTAGC-3’ 5’-CTCGGAGTGGATGTCCTCAT-3’ 
EBI3 5’-GAGAAGATGTCCGGGAAGG-3’ 5’-TCCTAGCCTTTGTGGCTGAG-3’ 
IL-6 5’-ACCAGAGGAAATTTTCAATAGGC-3’ 5’-TGATGCACTTGCAGAAAACA-3’ 
IL-12 p35 5’-GAGGACTTGAAGATGTACCAG-3’ 5’-CTATCTGTGTGAGGAGGGC-3’ 
IL-12 p40 5’-GACCCTGCCCATTGAACTGGC-3’ 5’-CAACGTTGCATCCTAGGATCG-3’ 
IL-17A 5’-GCCCTCAGACTACCTCAACC-3’ 5’-ACACCCACCAGCATCTTCTC-3’ 
IL-17F 5’-AATTCCAGAACCGCTCCAGT-3’ 5’-TTGATGCAGCCTGAGTGTCT-3’ 
IL-22 5’-CAGGAGGTGGTACCTTTCCTG-3’ 5’-TCTGGTCGTCACCGCTGAT-3’ 
IL-23 p19 5’-CCAGCGGGACATATGAATCT-3’ 5’-AGGCTCCCCTTTGAAGATGT-3’ 
IL-27 p28 5’-CTGGCAAGGTACAGGCTGA-3’ 5’-CAGGTGACAGGAGACCTTGG-3’ 
JAM-C 5’-CTGCCTGACTTCTTCCTGCT-3’ 5’-ATGTACCACTGGGTTTCGGT-3’ 
MUC2 5’-GTAGTTTCCGTTGGAACAGTG-3’ 5’-ATGCCCACCTCCTCAAAGAC-3’ 
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Supplementary Figure 1. Expression of IL-12 family members in normal and tumour tissue
of CPC-APC mice.
a-c: RT-qPCR analysis of cytokine mRNA expression in normal colon (N), tumours (T) and
mesenteric lymph nodes (MLN) of 5 months old CPC-APC or WT mice (a, b) or in tumours of
ApcIEC mice without or in combination with KrasG12D (K-Ras) or BrafV600E (B-Raf) alleles, activated
by intra-colonic administration of Adenovirus-Cre into ApcF/F, ApcF/F/K-ras-LSLG12D or ApcF/F/
BrafV600E mice (c). d,e: Immunostaining for IL-23 (d) or IL-23-driven GFP in CRC, and co-staining
of F4/80+ cells (e). Arrows indicate positive cells. f: Flow cytometric analysis of single cell
suspensions isolated from mesenteric lymph nodes (MLN) or colorectal tumours of Il23-/- CPC-
APC mice stained with anti-CD11b antibody. Live/Dead-CD45+ are shown. Data represent
averages  s.e.m., n=6 for a and b, n=3 for c. p=0.006 for IL-12p35 in a. Differences between the
different tumour models in c are not significant. * p<0.05. Scale bars, 50 m.
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Supplementary Figure 2. IL-23 signaling promotes colorectal tumour development and
growth.
a: Colonic tumours from 4.5 months old Il23r-/-/CPC-APC and control CPC-APC mice were
enumerated and measured. n=8, p=0.081, 0.041, 0.024, respectively. b,c: Paraffin sections of
colons from Il23-/-/CPC-APC or control CPC-APC mice were stained with active caspase 3 and E-
cadherin antibodies, TUNEL kit or a Ki67 antibody and TUNEL-positive apoptotic or Ki67 positive
proliferating cells were quantified. n=12, p=0.001 for proliferation index (c). d: Quantification of
phospho-STAT3high cells in colonic tumours of Il23-/-/CPC-APC or control CPC-APC mice (see Fig.
1g). 4 fields from different sections of 5 independent tumours were counted. p=0.0045. Data
represent averages  s.e.m. *p<0.05. Scale bars, 50 m.
Ki67
Caspase 3
b
E-cadherin
APC x IL-23+/+ APC x IL-23-/-
49
SUPPLEMENTARY INFORMATION
4  |  W W W. N A T U R E . C O M / N A T U R E
RESEARCH
0
2
4
6
8
10
N T
IL-22
0
1
2
3
4
5
N T
IL-17F
0
0.5
1
1.5
2
N T
IL-17A
0
0.2
0.4
0.6
0.8
1
1.2
1.4
N T
IL-6
IL-23 +/-
IL-23 -/-
0
1
2
3
Size (mm)
0
5
10
15
20
Number
WT
IL-23-/- BMT WT  BMT
IL-23-/-
a b
X
10
-3
e
*
c
IL-23 BMT
-/-+/-
*
d
X
10
-6
*
X
10
-3
*
X
10
-5
*
BMT
0
5
10
15
Number
0
1
2
3
Size (mm)
IL-23R-GFP BMT
gfp/gfp+/+
*
0
5
10
15
20
25
Load
+/+ +/+
*
0
10
20
30
40
50
Load
-/-+/- -/-+/-
*
gfp/gfp gfp/gfp
Supplementary Figure 3. The pro-tumourigenic function of IL-23 and IL-23R is exerted within
hematopoietic cells.
Six weeks old CPC-APC mice were lethally irradiated (2 x 600 rad) and transplanted with bone
marrow from Il23-/-, Il23rgfp/gfp or WT donors and analyzed 4-4.5 months later. a,b: Representative
histology (a) and gross appearance of tumour-bearing colons (b) from chimeric CPC-APC mice
reconstituted with WT or Il23-/- bone marrow. c,d: Quantification of tumour development in chimeric
CPC-APC mice reconstituted with Il23-/- (c) or Il23rgfp/gfp (d) bone marrow. n=5, p=0.024, 0.011 for
size and load of Il23-/- bone marrow transfer, and 0.023, 0.043 for Il23rGFP bone marrow transfer,
respectively. e: RT-qPCR analysis of cytokine mRNAs in tumours (T) and adjacent normal colon (N)
of chimeric CPC-APC mice reconstituted with control or Il23-/- bone marrow. n=6, p=0.0066, 2.3x10-
5, 0.014 and 0.0032, respectively. Data represent averages  s.e.m. *p<0.05. Scale bars, 500 m.
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Supplementary Figure 4. IL-17R signaling promotes growth and progression of colorectal
tumours.
Tumours from 5 months old Il17ra-/-/CPC-APC and control mice were analyzed. a: Tumour number,
size and load. n=7, p=0.014, 0.045, 0.011, respectively. b: H&E staining of colon sections from CPC-
APC mice of the indicated genotypes. c: Distribution of tumour sizes among all detectable tumours.
n=7, p=0.045 for tumours bigger than 3 mm. Data represent averages  s.e.m. *p<0.05. Scale bars,
200 m.
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Supplementary Figure 5. Signaling through TLRs is important for CRC tumour growth.
Six to seven weeks old CPC-APC mice were lethally irradiated (2 x 600 rad) and transplanted with
bone marrow from Tlr2,4,9-/- or WT donors and analyzed 4.5 months later. Quantification of tumour
size and load in chimeric CPC-APC mice is presented. n=5, p=0.025, 0.049 respectively. Data
represent averages  s.e.m. *p<0.05.
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Supplementary Figure 6. IL-18R signaling in hematopoietic cells is not required for IL-23
induction and growth of colorectal tumours.
Six weeks old CPC-APC mice were lethally irradiated and transplanted with Il18r-/- or WT bone
marrow and sacrificed for analysis 4 months later. a: Single cell suspensions from normal colons,
tumours and MLN were prepared and CD11b+ cells were sorted by positive selection on magnetic
beads. IL-23p19 mRNA expression was measured by RT-qPCR. b: Tumour number, size and load
were determined. n=5. None of the differences (number, size and load) are significant. Data
represent averages  s.e.m.
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Supplementary Figure 7. Human CRC and mouse colorectal tumours display dysregulation of
mRNAs encoding barrier and junctional proteins.
a,b: Total RNA was isolated from frozen tumour (T) and tumour-free (N) colon tissue of CRC patients
(a) or tumour bearing CPC-APC mice (b) and subjected to RT-qPCR analysis of indicated mRNAs.
Human: n=7, p=0.078, 0.025, 0.016, 0.025, 0.0065 for JAM-A, JAM-B, claudin-5, claudin-7, and
Muc2, respectively; Mouse: n=12, p=0.0012, 0.0035 and 0.0027 for JAM-C, claudin-4 and Muc2,
respectively. Data represent averages  s.e.m. *p<0.05.
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Supplementary Figure 8. Mouse colorectal tumours display dysregulation of barrier and
junctional proteins.
Paraffin-embedded colon sections from CPC-APC mice were stained with antibodies to claudin 4,
claudin 7, JAM-A or JAM-B and analyzed by fluorescent microscopy (a) or with claudin 3 and
claudin 5 specific antibodies (b). Normal (N) and Tumour (T) areas are shown. Scale bars, 50 m.
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Supplementary Figure 9. Early human adenomas and mouse rapidly transformed colons
display upregulation of cytokines and dysregulation of barrier proteins.
Total RNA was isolated from frozen human adenoma tissue removed during colonoscopy (T) and
matching tumour-free (N) colon tissue (a) or from Cdx2ERT-Cre x ApcF/F and control mice injected 3
times with tamoxifen and left for 20 days for rapid colonic transformation (b). RNA was subjected to
RT-qPCR analysis of the indicated transcripts. n=5, p=0.056, 0.024 for IL-23p19 and IL-17A in a. n=5,
p=0.018, 0.014 for IL-23p19 and MUC2 in b. Data represent averages  s.e.m. * p<0.05.
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Supplementary Figure 10. Scheme: “Tumour elicited inflammation” is triggered by the classical
genetic pathway that drives colorectal tumourigenesis and can further stimulate tumour
progression.
Inactivation of tumour suppressor APC is the first step in the classical genetic pathway of colorectal
tumourigenesis, leading to persistent activation of -catenin signaling. We propose that -catenin
signaling in early neoplastic lesions induces altered tissue homeostasis and disruption of the epithelial
barrier, including downregulation of mucin 2 expression due to failed goblet cell differentiation and
disruption of tight junctions. Tumour-specific deterioration of barrier function allows commensal
microflora and microbial products to penetrate the adenomas, activate TLR-MyD88 signaling and
induce IL-23 in tumour associated macrophages (TAM). IL-23 regulates tumour elicited inflammation
and the Th17-like response, particularly its effector cytokines that include IL-17A and IL-6, to activate
transcription factor STAT3, which together with -catenin enhances the proliferation and growth of
adenoma cells. Tumour elicited inflammation further contributes to tumour progression and malignant
conversion by multiple mechanisms, some of which many also involve STAT3 activation. Tumour
promoting events are in ‘blue”, tumour suppressors are in ‘red’.
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Supplementary Figure 11. Generation of F/F and -/- mice.
a: Targeting strategy. Two LoxP sites were introduced into introns 1 and 3 of the Il23r gene, such that
Cre-mediated deletion results in excision of exon2 and exon3, which encode the ligand-binding
extracellular portion of the receptor. The targeting construct was introduced into Bruce 4 C57Bl6 ES
cells and homologous integrants were used to generate Il23rF/F mice. b: Southern blot screening of
Bruce 4 ES clones. Representative clones are shown. c: Selected clones were injected into C57BL/6-
Albino blastocysts and transferred to pseudopregnant females. Chimeric offspring were bred with
C57BL/6-Albino partners to generate F1 mice that were screened for integration by Southern analysis
(for more details see Methods). Resulting mice with the Il23rSA-flox-neo allele were crossed with
C57BL/6-FLPe mice to facilitate recombination between Frt sequences and generate the Il23rflox
allele. The null allele was generated by crossing Il23rF/F mice with CPC-Cre transgenic mice (for more
details see Methods). Complete ablation of IL-23R was confirmed by Q-RT-PCR of spleen and
tumour-derived cells.
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